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ABSTRACT
Role of A2 Adenosine Receptors in the Regulation of Coronary Flow
Maryam Sharifi Sanjani

One out of three individuals suffer from one form of cardiovascular disease, out of which,
about 6,000,000 individuals suffer from coronary heart disease. Adenosine has long been known
to play a role in coronary flow (CF) regulation; however, the individual role of A2A and A2B
adenosine receptors (AR) and their contribution is yet to be fully elucidated. The purpose of this
study was to characterize the pharmacology of both A2 ARs in coronary arteries (CAs), in
addition, to identifying their role in reactive hyperemia, and their signaling mechanisms. We
hypothesized that A2 ARs mediate an increase in CF, in addition, to being involved in metabolic
control of CF. Therefore, in this study, we investigated CF changes due to exogenous activation
of A2A and A2B ARs, in addition, to their endogenous activation during coronary reactive
hyperemia, when metabolic factors, such as adenosine, play a pivotal role. We used the well
established Langendorff isolated heart system as well as selective and non-selective AR agonists
and antagonists, and A2A and A2B AR single and double knockout mice. We found that activation
of both A2A and A2B ARs induces an increase in CF, albeit with different pharmacological
profile. Further, in A2BKO mice, A2AARs are up-regulated in order to compensate for deletion of
A2BARs. These findings may suggest that both A2 ARs are capable of increasing the CF in
conditions when a sufficient level of adenosine is available. However, we also found that only
A2AARs contribute to CF changes in coronary reactive hyperemia, which may suggest that
A2BARs may be activated in more severe conditions such as longer ischemic conditions, where
adenosine levels are significantly augmented. We next investigated signaling pathways involved

in A2 AR-mediated effects. We found that non-mitochondrial KATP channels are a major end
effectors in A2AR-induced increase in CF. What is more interesting is that we illustrated that
H2O2 mediates adenosine’s effect on CF and that is coupled to adenosine-mediated effect on
KATP channels. From these data, it can be concluded that A2A and A2B ARs may regulate CF in
different conditions, albeit, maybe through the same signaling pathway.
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CHAPTER ONE

INTRODUCTION

2
Adenosine, produced by all cells, is an endogenous purine nucleoside with
various physiological effects induced through its four subtypes of receptors A1, A2A, A2B,
and A3. Figure 1.1 illustrates the chemical structure of adenosine. Adenosine induces its
effects All adenosine receptors (AR) are G protein coupled receptors (GPCR) and have
their own pharmacological profile and affinity for adenosine, tissue distribution, and
effector coupling. Therefore, effects mediated through adenosine depend on the AR
subtype activated.
Generation of adenosine and its metabolism
In physiological conditions, adenosine is produced from intracellular conversion
of S-adenosyl-L methionine (SAM) to S-adenosyl-L-homocysteine (SAH) which then is
converted to adenosine and homocysteine by SAH-hydrolase (30, 48) (Figure 1.2).
Cytosolic adenosine can become phosphorylated via adenosine kinase to AMP in
addition to getting converted to inosine by adenosine deaminse (ADA), especially at high
levels of adenosine. Intracellular adenosine is transported down the concentration
gradient into the extracellular space via equillibrative membrane transporters. Adenosine
can also be produced extracellular through successive dephosphorylation of ATP to ADP
and then ADP to AMP, which then goes under hydrolysis via membrane-bound ecto-5′nucleotidases CD39 and CD73 in order to form adenosine. By the action of ADA,
extracellularly produced adenosine can also be further converted to inosine which is
finally broken down to uric acid that is excreted in urine. However, adenosine can also
get re-converted to AMP via the enzyme adenosine kinase (AK). Nevertheless,
extracellularly produced adenosine can also be transported into the cell via concentrationand/or sodium-dependent transporters (Figure 1.2). In addition to being metabolized,
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adenosine acts on its specific receptors to induce various physiological effects (43, 48,
82).

4
Figure 1.1 Adenosine structure

Figure 1.2 Production of adenosine under physiological conditions. Scheme adapted
from Koos et al. (82)
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Coronary flow regulation
Coronary arteries (CAs) play a pivotal role in determining the oxygen and nutrient
supply of the myocardium by regulating the coronary flow (CF). Myocardial perfusion is
regulated by several factors released from endothelial cells, smooth muscle cells, and
cardiomyocytes that affect the coronary vascular tone. It is well known that physical
forces induce coronary responses known as myogenic and flow-induced (shear stress)
vascular control that determine the vascular basal tone and CF (Figure 1.3). Also,
metabolic factors such as adenosine have been shown to mediate CA responses during
metabolic stimulation (active hyperemia), autoregulation, and/or reactive hyperemia
(Figure 1.3). Moreover, sympathoneural factors such as the effect of β adrenoceptors
(ADR) are reported to affect the coronary tone through endothelium-dependent and –
independent manners (Figure 1.3).
Pressure-induced myogenic constriction importantly contributes to autoregulation
of local blood flow, which also acts as a protective measure from sudden increases in
arterial pressure (88). Given that this constriction allows resistance arteries, such as
coronary arterioles, to constrict or dilate in response to vasoactive mediators and changes
in intraluminal pressure, it counts as an essential component of basal microvascular tone
where vascular resistance is tightly regulated (19). The myogenic response occurs
independently of the endothelium and perivascular nerves and is, therefore, an inherent
property of vascular smooth muscle cells (85, 98). Smooth muscle cells have stretchactivated cation channels that, when activated, induce an inward current leading to cell
membrane depolarization and constriction (22-23, 160). Previous studies have shown that
increased intraluminal pressure leads to depolarization of smooth muscle cells and the
opening of Ca2+ channels, such as Ca2+-activated K channels (BKCa), responsible for
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increased intracellular Ca2+ leading to the contraction and the increase in myogenic tone
(53-54, 108). Several endogenous mediators, such as cytochrome P450 metabolites, have
been suggested to be involved in myogenic tone control via activation of BKCa channels
(158). The CA myogenic tone is also proposed to be regulated by several molecular
signaling pathways, such as, PKC pathway (29, 83, 99) and MAPK/ERK1/2 pathway
(76-78). Moreover, the myogenic constriction in CA is suggested to antagonize EDHFmediated dilation; it was reported that activation of BKCa channels reduces myogenic
constriction and profoundly increases EDHF-mediated dilation in CA (54).
An increase in wall shear stress results in the release of various factors from the
endothelium that subsequently act on smooth muscle cells in order to induce vasodilation
(86, 122, 150, 165). This illustrates the release of endothelium-derived factors that may
limit myogenic constriction. Endothelium-derived nitric oxide (NO), suggested as
endothelium-derived relaxing factor (EDRF), was proposed to regulate the coronary
reactive hyperemia responses (80, 150, 165). However, other non-NO and non-prostanoid
endothelium-derived substances, referred to as endothelium-derived hyperpolarizing
factors (EDHFs), were found to play an important role in the regulation of CA vascular
tone. Epoxyeicosatrienoic acids (EETs) (46, 128), H2O2 (96, 101, 163), and K+ (6) are a
few suggested EDHFs in coronary arteries to highlight. Liu et al. showed that
endothelial-derived H2O2 was critical in human CA dilation to shear stress (90, 101). The
same group also suggested that mitochondria are the source of the H2O2 generation that
plays a role in flow-induced human CA dilation (90). Miura et al. reported that shear
stress induces endothelium-dependent vasodilation through CYP450 metabolites leading
to hyperpolarization of smooth muscle cells through BKCa channels in human coronary
arterioles (103). It should be highlighted that human CAs in these studies are dissected
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from patients with cardiovascular disease, which may lead to different physiological
responses than true controls, the tissues from healthy individuals. Nevertheless, previous
studies have shown that endothelial production of NO can be triggered by mechanical
shear forces or CF-induced pulsatile strain (154-155). It was demonstrated that NO
contributes to the coronary responses in reactive hyperemia (167)and that adenosine is
involved in CA flow-induced dilation and enhanced coronary response to pulsatile
perfusion(87, 117, 169), which suggests the existence of a cooperative interaction
between adenosine and the local flow regulation mechanisms.
It is well established that CF is regulated by the metabolic state of the heart (44)
(Figure 1.3). Berne’s adenosine hypothesis suggests that increases in myocardial oxygen
consumption decreases myocardial oxygen tension (pO2) which leads to the release of
adenosine from cardiomyocytes (8, 43, 159). Furthermore, a role for H2O2 in metabolic
CA vasodilation has been established (72, 116, 164). Chilian et al. suggested that H2O2
production increases in proportion to cardiac metabolism in order to couple the coronary
blood flow to myocardial oxygen tension (131). On the other hand, increasing evidence
has shown the involvement of KATP channels in metabolic CF adjustment through
different approaches such as pacing-induced tachycardia (73), pharmacological metabolic
stimulation (110), and exercise (36). Further, coronary arteriolar smooth muscle KATP
channels (42, 124-125) and BKCa channels were reported to contribute to the basal CF
regulation (53). There is evidence that during exercise, coronary NO production is
increased in the heart (136), likely due to an increase in endothelial shear stress
secondary to the increased CF rate (9, 149). Nevertheless, Chilian et al. demonstrated that
CA vasoconstriction induced by inhibition of NO was counterbalanced by coronary
vasodilation, indicating that many compensatory vasomotor adjustments occur in order to
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maintain the CF (71). And finally, the knowledge that prostaglandins may also act as
local chemical mediators to control coronary perfusion to adapt to the metabolic demands
of the heart should be considered (135).

9
Figure 1.3 Several reported pathways for metabolic vasodilation of coronary
arteries. Scheme adapted from Koos et al. (82).
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It has been known that neurotransmitters released from nerve endings are known
to affect the coronary vascular tone. Sympathetic stimulation-mediated coronary
vasoconstriction is capable of competing with local metabolic control to lower coronary
venous oxygen tension (44). The autonomic effects on CF regulation have been studied at
rest and during exercise through different approaches such as after surgical or chemical
denervation of the heart or in the presence of selective autonomic receptor antagonists. It
was reported that cardiac neural ablation did not impair the ability to maintain the
exercise level, although the initial hemodynamic adjustment to exercise was delayed (52).
It is established that blockade of α2-adrenoceptors (ADR) can affect the CF through three
mechanisms: a) blockade of prejunctional αADR which interrupts the negative-feedback
control of norepinephrine release leading to an increase in norepinephrine levels and
induction of cardiac ßADR stimulation and an increase in CF (60, 62); b) αADR
blockade can increase CF by interrupting vasoconstriction mediated by postjunctional α 1
and α2ADRs located on CA smooth muscle cells; and c) α2 ADR on CA endothelial cells
can stimulate release of nitric oxide (NO), which can oppose the αADR-mediated
vasoconstriction (20, 65). On the other hand, it was reported that norepinephrine brings
about human coronary vasodilation through ß2ADR (139) that involves NO and KATP
channels (100). Previous studies suggested that ß2ADR-mediated CF regulation is
minimal under resting conditions in dogs (5, 61) while, βADRactivation was shown to
contribute to coronary vasodilation during exercise in a feed-forward manner (104-105,
153). β2ADR activation during exercise causes a significant degree of CA dilatation
independent of myocardial effects of β1 ADR stimulation (31, 94). Overall, the consensus
is that βADR blockade causes a greater reduction in CF compared to myocardial oxygen
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consumption, resulting in increased oxygen extraction by the heart which demonstrates a
direct feed-forward for βADR CA vasodilatory effect.
In this thesis, based on previous studies on adenosine and the existence of broad
factors involved in the regulation of CF, we elaborate on the role of adenosine, KATP
channels, and H2O2 in addition to a brief look at β adrenoceptors, as a sympathoneural
factor, in light of adenosine as the main focus.

12
Figure 1.4 Previously reported major signal transduction pathways in the regulation
of coronary flow. Adapted from Komaru et al. (81)
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Role of adenosine in coronary flow regulation
The heart has a small anaerobic metabolic capacity and, therefore, is essentially
dependent on CF in order to provide the heart with oxygen on a beat to beat basis. Some
also say that heart function is comprised of continuous sequential episodes of transient
increase in CF, called reactive hyperemia (RH), with the decreased flow occurring during
the systole and the RH response occurring during the diastole. Additionally, during
conditions such as coronary vasospasm or even exercise the myocardium is also
responsive to acute periods of decreased CF by means of RH. Nevertheless, as
mentioned, the increase in CF during more aggressive conditions such as exercise or
angina plays a crucial role in providing the heart with necessary oxygen. However, it is
interesting to note that the myocardium is reported to only extract about 75% of the
delivered oxygen at rest and that the seemingly high level of repayment during episodes
of RH only provides oxygen repayment ratios of between 26-82% (129), which suffice to
say that myocardium has a small oxygen extraction reserve and that the contribution of
any vasodilatory factor plays a crucial role for the regulation of CF and the efficient
oxygen supply and, hence, cardiac function. Needless to say that although the myocardial
oxygen supply (in the form of blood flow or oxygen extraction) is small, the myocardial
oxygen consumption can increase up to five fold when needed (43).
In 1963, Berne et al. proposed the adenosine hypothesis (7). The idea was that the
myocardial oxygen supply over oxygen consumption ratio is reflected in the intracellular
myocardial oxygen tension (pO2). For example, if myocardial oxygen supply over
consumption ratio decreases (as during exercise), the myocardium encounters a fall in
pO2 which leads to the breakdown of adenine nucleotides (ATP, ADP, AMP) and, hence,
generation of adenosine. The produced adenosine then diffuses out of the cell to act on its
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receptors on coronary arteriolar smooth muscle cells (through an endothelium-dependent
and –independent manner) in order to cause vasodilation. This increase in CF delivers
more oxygen to the myocardium and, thus, returns myocardial pO2 back toward the
normal range (Figure 1.5). The adenosine hypothesis is also a transmitter hypothesis
which suggests that adenosine transmits information regarding the status of one cell type
such as cardiomyocyte to another cell type such as arteriolar smooth muscle by diffusing
across the interstitial space (43, 48). Therefore, Berne’s adenosine hypothesis suggests
that adenosine coordinates the myocardial oxygen consumption to CF (Figure 1.5). The
role of each AR subtype in the regulation of CF has been extensively studied.
Adenosine receptors classification and characteristics
Adenosine receptors were initially classified into A1 and A2 subtypes based on
their potency for ligands and antagonism by methylxanthines (91). Subsequently
subclassiﬁcation of A2 into A2A and A2B subtypes was pharmacologically based upon the
high afﬁnity A2A and low affinity A2B binding sites in rat brain (24). All ARs are seven
transmembrane GPCR with approximately 21–28 amino acids in each transmembrane
region. The A2AAR is 409 and 410 amino acids long in human and mouse, respectively.
A2AAR is the largest of all ARs due to its extended C-terminus of no known function
(121). Overall, there is relatively low level of amino acid homology between different
ARs in a single species in addition to the same AR between species which may contribute
to the different ARs-mediated effects observed in different species.
The N-terminus of ARs are extracellular and it was shown that all ARs other than
A2AAR have a palmitoylation site near the C-terminus (1). Furthermore, all ARs are
glycosylated on their 2nd extracellular loop (121) and although the 3rd intracellular loop is
involved in both A1 and A2AAR G protein coupling, the C-terminus is only involved in
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A1 AR G protein coupling (151). It was also reported that the A2AAR phosphorylation of
intracellular loop is involved in this AR desensitization (118). Currently, all four ARs are
cloned and their expressions in various tissues have been extensively studied.
The A2AAR gene has been localized to chromosome 22q11.23 (27, 92) and
chromosome 10 in human and mouse, respectively (162). However, the A2BAR gene has
been localized to chromosome 17p12-11.2 (69) chromosome 11 in human and mouse,
respectively (162). A2AAR was the first AR genetically modified in a murine model (89).
The A2AAR knockout (KO) mice were developed in three different genetic backgrounds
of CD1, congenic C57B L/6, and pure 129-Steel (17-18, 89) while A2BAR has been
recently developed only in C57BL/6 background. A2AKO animals demonstrated several
central nervous system disturbances such as decreased exploratory activity, increased
aggressiveness and hypoalgesia (89). Furthermore, A2AKO mice with CD1 genetic
background were demonstrated to have increased blood pressure, heart rate, and platelet
aggregation (89) while an A2AKO mice on either a mixed 129Steel-C57BL/6 or congenic
C57BL/6 genetic background did not show any change in blood pressure(17, 26). While
there are relatively a large number of studies on A2AKO, there are not many studies using
A2BKO mice and, therefore, a better understanding of its functional effects or
compensatory mechanisms due to its genetic modification still remains to be fully
elucidated.
A2ARs: The presence of both A2A and A2BARs on coronary endothelial and
smooth muscle cells and the pivotal vasoregulatory role of adenosine in human CA is
well established (37-38, 113, 130, 133). The involvement of A2AAR in the regulation of
CF in various other species has been also broadly reported (11, 37-38, 74, 106, 130, 133,
137, 142, 145, 167). Previous studies further suggest that metabolic vasodilatory factors
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such as adenosine are the primary mediators responsible for the CF regulation during RH
(21, 63, 114-115). In vivo studies in dogs showed a role for A2AAR in CF regulation
during RH (32), which further confirms the physiological role of adenosine. Zatta et al.
also confirmed this finding by using pharmacological approaches (11, 167). Furthermore,
it is proposed that A2AAR contributes to the coronary circulation basal tone since deletion
of A2AAR and application of SCH58261 (A2A selective antagonist) diminished the
baseline CF compared to WT hearts (137, 145).
Due to its lower affinity for adenosine, A2BAR is activated in conditions where a
significant increase in adenosine levels is observed, such as in ischemia (48). Also, a
previous study showed that A2BAR may not play a role in basal tone regulation of CF
since targeted deletion of A2BAR had no effect on the baseline CF (137). Additionally,
Tune et al. suggested no role for A2BAR in RH by means of indirect measures such as
using non-selective antagonist (11). Nevertheless, A2BAR is shown to be involved in the
regulation of CF, albeit may be with a lesser contribution compared to A2AAR (13, 106,
137, 142). Furthermore, recent studies suggested an interrelationship between A2A and
A2BARs subtypes since one compensates for the down-regulation/deletion of the other
(137, 145) through their up-regulation in coronary arterioles. In fact the involvement of
A2A and A2BARs and their down- or up-regulation is reported in many pathophysiological
conditions (2, 4, 41, 75). Regardless of this relationship, the differential expression of
ARs is shown to contribute to functional heterogeneity of human endothelial cells (45)
and the impairment of adenosine-related signaling contributes to the pathophysiology of
congestive heart failure (2). By benefiting from gene-modified models and
pharmacological approaches and by using selective adenosine analogs, we were allowed
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to better assess the role of A2ARs in the regulation of CF and, therefore, to better
understand the heterogeneity of CF in relation to A2ARs responses.
A1AR: There are previous reports from our laboratory suggesting that A1AR
negatively modulates the role of A2AARs and probably A2BARs in CF regulation (141,
144). The presence of only A2AARs and A2BARs on coronary endothelial cells may also
indirectly support this finding (113). Additionally, it was recently reported that in
Ossabaw swine A1 AR antagonism by DPCPX positively regulated basal CF. However,
although A1 AR may not play a major role in CF regulation, it has been shown that this
receptor mediates negative chronotropic effects which may indirectly affect the CF in
conditions where adenosine concentration is elevated enough to induce the chronotropic
effect of this AR subtype. Nevertheless, A1 ARs are known to protect the heart from
ischemia-reperfusion (107, 161, 168) and coronary atherosclerosis (preliminary data from
our laboratory (146)).
A3AR: Zhao et al. showed that high concentrations of A3 AR agonist, ClIBMECA, induced coronary vasodilation which was further blocked by A2AAR
antagonism (171). However, A3AR targeted deletion increased the A2AAR-mediated
response. This finding may suggest that A3AR also participate in CF regulation of
isolated murine hearts via negative modulation of A2AAR-mediated coronary vasodilation
(141). Additionally, single-nucleotide polymorphism (SNP) of I248L in A3 AR gene is
shown to be associated with coronary heart disease (120). Further studies are required to
better understand the role of A3 AR in CF regulation and responses.
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Figure 1.5 Berne’s adenosine hypothesis. Scheme adapted from Feigl et al. (43)
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Classically known signaling of adenosine receptors
As mentioned, each AR has its own pharmacological profile. Adenosine at its
basal concentration is sufficient to activate A1, A2A, and A3 ARs. However, due to its low
affinity for adenosine, A2BARs are activated in conditions where significant high levels
of adenosine are produced, such as in pathophysiological conditions. It is well established
that A1 and A3ARs are associated with Gi proteins while A2A and A2B ARs are coupled to
Gs proteins. The A1 and A3 ARs signal through Gi/o proteins and its activation leads to an
inhibition of adenylyl cyclase (AC) which causes a lowering of cyclic AMP (cAMP)
levels. The A2A and A2BARs signal through the Gs pathway and its activation leads to
stimulation of AC resulting in increased production of cAMP. Classically, ARs were
thought to induce their effects through inhibition (G i) or stimulation (Gs) of adenylyl
cyclase. However, it is becoming more and more evident that these receptors also activate
other pathways such as phospholipase C (PLC), mitogen-activated protein kinase
(MAPK), etc. In fact, signaling through the A1 AR can also lead to activation of IP3/DAG
through the PLC pathway (68, 143). Additionally, the A2B receptor signals through G s/q
and its activation can either result in increased cAMP or IP 3/DAG and Ca2+ levels.
Furthermore, ARs are now shown to be associated with the K+ channels, production of
reactive oxygen species (ROS) and activation of the arachidonic pathway (34, 50, 59,
111, 137).
Role of K+ channels in A2AAR-mediated coronary flow regulation
K+ channels play an essential role in determining the cell membrane potential and
regulating the contractile tone of arterial smooth muscle cells through controlling the
Ca2+ entry via voltage-dependent Ca2+ channels and, thereby, the contractility (67). There
are four types of K+ channels on CA smooth muscle and endothelial cells: voltage-
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dependent K+ (KV), Ca2+dependent K+ (BKCa), ATP-dependent K+ (KATP), and inward
rectifier K+ (Kir) channels. KATP channels are shown to be present on isolated coronary
artery cells (51, 140), in addition to KV channels which are known to be expressed on
coronary arteries (33, 66, 140, 156, 166). Additionally, BKCa channels are known to be
abundantly expressed on coronary smooth muscle cells and contribute to CA vasodilation
in different species (15, 64, 102), in addition, to Kir channels which are reported to be
present on both coronary smooth muscle and endothelial cells (119, 126, 140, 157, 166).
It is worth mentioning that K+ was suggested to be the EDHF in various vascular
beds (39-40). Additionally, in general, K+ channels have been suggested to be involved in
A2A and A2BARs-mediated hyperpolarization of CA (55-56, 74, 109, 112, 137, 170) and
in adenosine’s role in potentiating flow-induced CA vasodilation (84). Coronary
arteriolar smooth muscle KATP channels are tonically active under physiological
conditions. Indeed, in humans as well as in different animal species, application of
glibenclamide, a KATP channel blocker, resulted in a decrease in resting blood flow (42,
124-125, 137). Additionally, a primary role for KATP channels in mediating the sustained
dilation of CA during RH was suggested (167).
Adenosine is reported to activate KATP channels in rabbit isolated CA smooth
muscle cells (140) and in the A2A-induced effect in RH (11, 167). Additionally, a recent
study proposed that the decrease in CF produced by intracoronary glibenclamide may
cause metabolic changes of ischemia including the release of adenosine (35, 132). This is
an important observation, since it indicates that blockade of the endogenous vasodilator
system associated with KATP channel activity can cause coronary vasoconstriction
sufficient to result in myocardial ischemia (132). Adenosine-mediated activation of KATP
channels may be indirectly through release of some other mediators such as H2O2 (please
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see the role of H2O2 in A2AAR-mediated CF regulation section)(50). A study reported
that the effect of adenosine on endothelial KATP channels may be mediated via pertussis
toxic-sensitive G proteins and not through the release of NO and cGMP production,
whereas activation of smooth muscle cell KATP channels may not involve G proteins (59).
Moreover, the enhanced responsiveness to adenosine at lower CA intraluminal pressure
was suggested to be due to increased smooth muscle cell K ATP channels activity (169). In
addition to the A2AR-mediated pathway, one study suggested that adenosine also
activates KATP currents in single CA smooth muscle cells via A1 ARs (25). Nevertheless,
the signaling pathway due to the activation of endothelial KATP channels is yet to be fully
explored.
To date no patch clamp study has demonstrated the effect of adenosine on K V
currents in CA smooth muscle cells. However, in vivo studies have shown that 4aminopyridine, KV channel blocker, inhibited CA vasodilation induced by adenosine (11,
32, 56-58). Previous studies on CA smooth muscle cells also indicate the involvement of
PKC and PKA in the KV channel-mediated pathway (138, 140),which renders the
question whether adenosine induces the activation of KV channels through the PKC
pathway.
Role of H2O2 in A2AAR-mediated coronary flow regulation
H2O2 is suggested to act as EDHF in humans and mice (95, 97, 163).
Additionally, it was reported that H2O2 induces CA vasodilation through both
endothelium-dependent and –independent manners (147). Recent reports have established
the contribution of H2O2 in flow-induced dilation of isolated human CA (101) and in
reactive dilatation of rat isolated coronary arterioles (79). Yada et al. proposed that H2O2
(as an EDHF in vivo) plays an important role in CA autoregulation in cooperation with
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adenosine and NO (163). However, so far there are no reports showing the relationship
between H2O2 and adenosine-mediated coronary vasodilation, which lead to the basis of
our study.
It is worth mentioning that Berne’s adenosine hypothesis suggests that increases
in myocardial oxygen consumption decrease myocardial oxygen tension which leads to
the stimulation of the release of adenosine from cardiomyocytes (152), where A2AARs
have also been found to be expressed in both human and mouse (16, 93). Adenosine
induces CA dilatation through activation of sites on cardiomyocytes in addition to the
arteriole vascular bed itself (148). Furthermore, as mentioned, a role for H2O2 in
metabolic vasodilation has already been proposed (164) and Chilian et al. suggested that
H2O2 production increases in proportion to cardiac metabolism in order to couple the
coronary blood flow to myocardial oxygen tension (131). What is interesting to
appreciate is that both H2O2 and adenosine are released from cardiomyocytes and that
they may modulate the vascular tone through the cardiac myocyte (72). Therefore,
myocardium may be partly the source of both adenosine and H 2O2 released for the
regulation of CF. Our study is based on such similarities between adenosine and H2O2
(please also refer to chapter 4).
Relationship between adrenoceptors (ADR) and A2ARs in coronary flow regulation
Endogenous adenosine was reported to affect the norepinephrine release from
sympathetic nerve endings (127). The A2AAR-mediated facilitation of norepinephrine
release was also suggested to require activation of the PKC and PKA pathways (49)
which itself is proposed as an adenosine signaling pathway. It was reported that αADRmediated coronary vasoconstriction during exercise limits coronary perfusion in impaired
endothelial function situations (70). DeFily et al. further added to this finding by showing
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that, even in normal conditions, stimulation of αADR-induced vasoconstriction is masked
by autoregulatory control, by means of NO release and endogenous adenosine (28).
Furthermore, it was demonstrated that coronary RH responses due to adenosine are
blocked by αADRs when NO synthesis is interrupted (14). On the other hand, the
cardioprotective effect of carvedilol, a βADR blocker, was shown to be through an
adenosine-dependent mechanism (3). Additionally, it was demonstrated that βADRmediated inotropic responses were attenuated by adenosine (134). Therefore, overall
there is some evidence on similarities between ADR and AR cardiovascular effects and
signaling. However, there are no studies on the interaction or cross talk of ARs and
ADRs in the regulation of CF which was the basis of our new study (Please see our
appendix A).
Clinical applications
Adenosine and its agonist are currently being used in clinical settings; The
vasoregulatory properties of A2AARs are used clinically in humans for the diagnosis of
coronary artery disease through the use of adenosine (Adenoscan) as a substitute for
exercise stress testing for people who can’t exercise in myocardial perfusion imaging
(12). The use of Adenoscan has its own limitations due to its blocking effect on AV
conduction [due to activation of A1 ARs (10, 12)] and inducing bronchospasm [probably
due to activation of A1, A3 or A2BARs (47, 123)]. However, these side effects may be
alleviated by the development of more A2 ARs subtype selective agonists. A new A2AAR
selective agonist called Regadenoson (Lexiscan®) has been developed and approved by
FDA which is being used clinically in myocardial perfusion imaging. Additionally, in
many cardiovascular diseases such as coronary atherosclerosis, angina, and hypertension,
an attenuated vascular response to adenosine has been demonstrated where functional
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disturbance of smooth muscle or endothelial cells may be the underlying cause.
Therefore, it is important to better understand adenosine’s role in the regulation of CF, its
mechanism of action, and its interplay with other AR receptors, and/or its interaction with
the ADRs.
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Project Summary
Adenosine plays an important role in coronary flow regulation in physiological and
pathological conditions where AR expression modification may occur. Therefore, the
purpose of this investigation was to better understand the individual role and contribution
of A2 ARs in the regulation of coronary flow and their mechanism of action during their
exogenous and endogenous activation. In addition to better understand the heterogeneity
of CF responses by ARs, elucidation of ARs’ role in CF regulation would enable us to
develop therapies with less unwanted side effects or new enhanced medications for the
diagnosis and/or treatment of cardiovascular disorders. With this purpose in mind, the
following aims were developed:

Specific Aim 1: Elucidation of the role of A2 ARs in the regulation of coronary flow
Specific Aim 2: Identification of A2 ARs signaling pathways in coronary flow
regulation
Specific Aim 3: Characterize the role of A2 ARs in coronary reactive hyperemia
Specific Aim 4: Identify the role of H2O2 in A2 ARs’ signaling pathway during
reactive hyperemia
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RATIONALE AND LIMITATIONS
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The isolated perfused heart (Langendorff heart system), especially for small
animals, is one of the optimal approaches, having in mind, the quantity and quality of
data that can be obtained in a laboratory setting. Nevertheless, this approach has its own
advantages and disadvantages.
The isolated heart provides us with types of data, such as heart rate, left ventricle
pressure, and coronary flow, in the absence of the confounding effects of other
organs,systemic circulation, neurohormonal factors, etc. This characteristic is considered
as an advantage since it allows the distinction of aforementioned factors from cardiac
responses. The absence of neurohormonal and peripheral factors can often be
compensated for, if required; for example catecholamines or other neurotransmitters may
be included in perfusate and many other peripheral mediators can be added exogenously.
However, this approach can also be considered a disadvantage in the sense that it makes
the preparation one step further away from the physiological in vivo state. Nonetheless,
without a doubt, the isolated heart system provides us with the ability of performing
metabolic or pharmacological dose-response studies. Although one must take into
account the fact that, as an ex vivo preparation, the isolated heartundergoes deterioration
in time, but it is capable of providing data up to 3-4 hours.
Using the isolated heart system, we are also able to induce whole heart ischemia
through flow occlusion; this is an approach that we used for our reactive hyperemia
experiments. Anoxia or hypoxia at various degrees of oxygen deprivation (in the
presence of normal ﬂow) can also be easily imposed through manipulation of
oxygenation rate or amount. Therefore, this approach provides us with a powerful tool for
assessing many aspects of ischemia/hypoxia or even, if interested, ischemia-reperfusioninduced injury, in which case single coronary occlusion can be performed.
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It is important to know that we have two modes of operation of the isolated
perfused heart systems: constant flow and constant pressure. Whereas constant flow
perfusion eliminates a variable from the experiment, it also has the disadvantage that,
unlike constant pressure perfusion, autoregulatory coronary flow mechanisms are
overridden and, therefore, it does not provide us with data regarding coronary flow
regulation. Switching between constant flow and constant pressure modes of perfusion is
not very straightforward so that it can be feasible within a single experimental protocol.
However, currently, this system is now commercially available through ADInstruments
Ltd. which allows us to switch instantly between constant pressure and constant flow
modes of perfusion, enabling perfusion pressures and coronary flow to be controlled over
a wide range. This feature is of considerable advantage in many studies of vascular
function.
Using isolated perfused heart, several types of data can be gathered; for the
purpose of morphology and vascular anatomy studies, heart or vascular fixation can be
easily performed through coronary perfusion of required agents and a sequential analysis
using light or electron microscopy. Additionally, the heart can be sliced, starting at the
apex of the heart and working towards the base, for histology studies of coronary arteries.
The whole heart can also be used for gross morphology such as is required during infarct
size or cardiac hypertrophy studies. From a biochemistry/physiology point of interest,
arterio-venous substrate concentration differences for metabolites, oxygen, and a host of
other factors involved during physiological and extreme metabolism can be measured.
Additionally, measurement of cellular constituents such as enzymes and proteins can be
performed for the assessment of tissue injury due to the influence of, for example, various
conditions such as ischemia/reperfusion or hypoxia. Microelectrodes can further be used
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for continuous measurement of interstitial K+, Ca2+, pH or monophasic action potentials.
With all that in mind, using isolated heart perfusion the coronary perfusion, can be used
for delivery of vectors in gene transfer studies where adenovirus or other vectors can be
selectively delivered to the coronary artery vasculature and hence providing us with a so
called “organ specific gene modification”, which may replace whole animal knockout
models as an approach which may exclude the effect of compensatory mechanisms due to
the general whole animal gene modification.
From a more functional standpoint, using the isolated heart system,
electrocardiographic recordings allow the detection, identification, and quantification of
cardiac arrhythmias. Furthermore, the Langendorff preparation provides valuable
information on left ventricular systolic and diastolic pressures and derivatives such as
dp/dt. Various ultrasound techniques, such as echocardiography and Doppler, can also be
used for measurements of cardiac wall thickening, stroke volume, cardiac output,
coronary flow velocity, etc. While most studies with the isolated perfused heart are
focused on the function and malfunction of the cardiomyocyte, using contractile and
metabolic endpoints, it should be highlighted that Langendorff heart system can be used
to study vascular reactivity, endothelial and smooth muscle function, and the effect of a
variety of agents and drugs on coronary flow. Indeed, the isolated heart has been the
foundation of much of the work on the no reflow phenomenon where A2 ARs agonists are
currently being clinically investigated as an approach for reduction of reperfusion injury.
Nevertheless, even from basic therapeutic approaches, the isolated heart preparation is
reliable for assessing the direct cardiovascular effects of various therapeutic agents in
terms of contractile function, electrical activity, or metabolic function. This preparation
allows us to perform dose-response studies with reproducibility and precise control of
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agent concentration. An additional advantage is that we are able to washout drugs from
the circulation by replacing perfusion fluids which itself can be an excellent approach to
study drug tachyphylaxis or desensitization.
There are also further important issues to consider when using the isolated heart
system. Like so many other aspects of heart perfusion, the decision of whether to pace the
heart or not, is based on a compromise between protocol requirements and quality of
data. Heart rate in isolated hearts, when left to contract spontaneously, undergoes a
progressive time-dependent decline. Spontaneous heart rate, in a perfused heart system, is
usually significantly below the physiological normal rate. Mouse heart rate, in an in vivo
preparation, is about 500 beats/min, whereas heart rate of about 380 beats/min, can be
expected in the ex vivo preparation. This decline in baseline heart rate, of course, adds an
additional variable, which itself may also vary among the animals. Moreover, this decline
in heart rate also adds variability to the measurements obtained for left ventricular
pressure. During an experiment, the worsening of HR depends on a large number of
factors including the skills of the worker, avoidance of injury, the species being used, the
composition of the perfusion fluid, the drugs used, age, HR and work load, and the
temperature at which the studies are carried out. During a Langendorff heart preparation
experiment, a deterioration rate of contractile function of about 5-10% per hour is
expected. Therefore, the rate of deterioration should be taken into account for the
interpretation of studies and the experiments should be more or less time-matched with
corrections for baseline deterioration when comparing groups.
Use of the isolated heart perfusion approach is reported in many large animals
such as pigs, monkeys, sheep, dogs and even humans. Nevertheless, such studies are less
frequently performed due to many limiting factors such as high cost, presence of greater
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variability in results, need forf large volumes of perfusion ﬂuid and specialized
equipment required. The availability of transgenic technology for mice undoubtedly
resulted in increasing numbers of studies using murine preparations. Indeed, one of the
reasons to use mouse, in our laboratory, was the availability of AR KO mice. Currently,
the literature consists of an increasing number of studies which employ mouse hearts
although the high HR ofmice may set some limitations for translation of data obtained
from this species to human studies. Another limitation in the use of mice, in some studies,
is the very small size of all organs or tissues. For example, the size of many arteries, such
as large conduit coronary arteries, is in ~80 µm range, which shows a very smaller size
range for the coronary resistance vessels. The size of these vessels somehow limits the
study of coronary arteries in that the isolation of the actual resistance vessels is extremely
challenging. Also, the use of a larger number of animals is required in order to obtain
sufficient amount of tissue for the purpose of even basic experiments such as RT-PCR or
western blot. Another limitation with the use of mice is the miniaturization of equipment;
handling of rat hearts, for example, has a great advantage over smaller hearts from mice
where intraventricular pressure recordings are more difficult. The rat does, however,
suffer from very short action potential duration which can limit its value in terms of
translation of data to human studies of arrhythmia and antiarrhythmic drugs. Other
species, such as the rabbit, suffer problems with anesthesia and the guinea-pig heart
differs from other species in that the coronary vasculature is totally collateralized,
effectively preventing the study of regional ischemia in this species. Thus, as no ideal
species or setting exists, in selecting a species or preparation for a specific study, it is
crucial to recognize and appreciate the disadvantages and advantages.
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CHAPTER THREE

Contributions of A2A and A2B adenosine receptors in coronary flow responses in
relation to KATP channel using A2B and A2A/2B double knockout mice
American Journal of Physiology, September 2011
(Used with permission from Am J Physiol Heart Circ Phsyiol, appendix B)
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Abstract
Adenosine plays a role in physiological and pathological conditions and A2 adenosine
receptors (AR) expression is modified in many cardiovascular disorders. In this study, we
elucidated the role of A2BAR and its relationship to A2AAR in coronary flow (CF)
changes using A2B single (KO) and A2A/2B double (DKO) knockout mice in Langendorff
setup. We used two approaches: a) selective and non-selective AR agonists and
antagonists, and b) A2A and A2BKO and A2A/2BDKO. BAY60-6583 (selective A2B
agonist) had no effect on CF (ml/min/g) in A2BKO while it significantly increased the
WT CF (maximum of 23.3±9). NECA (non-selective AR agonist) increased the CF in
A2BKO (maximum of 34.6±4.7) to a significantly higher degree compared to WT
(maximum of 23.1±2.1). Also, CGS21680 (selective A2A agonist) increased the CF in
A2BKO (maximum of 29±1.9) to a significantly higher degree compared to WT
(maximum of 25.1±2.3). SCH58261 (A2A selective antagonist) inhibited the NECAinduced increase in CF to a significantly higher degree in A2BKO (19.3±1.6 vs. 0.5±0.4)
compared to WT (19±3.5 vs. 3.6±0.5). NECA did not induce any increase in CF in
A2A/2BDKO while a significant increase was observed in WT (maximum of 23.1±2.1).
Furthermore, mitochondrial KATP channel blocker 5-hydroxydecanoate had no effect on
NECA-induced increase in CF in WT while NECA-induced increase in CF in WT
(17.6±2), A2AKO (12.5±2.3), and A2BKO (16.2±0.8) was significantly blunted by KATP
channel blocker, glibenclamide, to 0.7±0.7, 2.3±1.1, and 0.9±0.4, respectively. Also,
CGS21680 (22±2.3), and BAY60-6583 (16.4±1.60)-induced increase in CF in WT was
significantly blunted by glibenclamide to 1.2±0.4 and 1.8±1.2, respectively. In
conclusion, this is the first evidence supporting the compensatory up-regulation of
A2AAR in A2BKO mice and demonstrating that both A2A and A2BARs induce CF changes

56
through KATP channels. These results identify AR-mediated CF responses which may
lead to better therapeutic approaches for the treatment of cardiovascular disorders.

Introduction
Adenosine is an endogenous nucleoside which is released through the breakdown
of adenine nucleotides. Adenosine’s cardiovascular effects are mediated through
activation of its four subtypes of receptors (AR), namely, A1, A2A, A2B and A3. Activation
of A1AR results in negative chronotropic and ionotropic effect, and a decrease in
coronary flow (CF) (68) while other studies suggest that the activation of both A1 or
A3 ARs prior to ischemia is cardioprotective (6, 30). However, adenosine is shown to play
a vasoregulatory role in human coronary arteries (16-17, 62-63). It is well established that
the activation of A2AAR induces positive inotropic effect and that A2AAR plays a major
role in the regulation of CF in ex vivo models (67, 69). Additionally, in vivo studies in
dogs showed the involvement of A2AAR in CF (reactive hyperemia) regulation (5, 77)
and thus, supporting a physiological role for adenosine. Adenosine-induced effects are
species-dependent (20, 23). For example it is reported that guinea pig coronary
vasodilation is more sensitive to adenosine compared to rats (72). Furthermore, few
studies show that A2BAR acts as a vasoconstricting as well as a vasodilating factor in
different vascular beds (13, 57), in addition, to playing a cardioprotective role during
ischemia/reperfusion (14-15, 30). Nevertheless, there are no reports fully elucidating the
individual and relative role of A2BAR in relation to A2AAR in coronary vasodilation. Our
group and others have previously suggested a role for A2BAR in coronary artery
vasodilation by means of indirect measures such as using non-selective agonist and
antagonists and A2AKO mice (48, 67) which are in accordance with previous reports
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showing A2AR-mediacted vasodilation in isolated human coronary arteries (39, 63).
Furthermore, this laboratory has shown the presence of A2B and A2AARs in human and
porcine coronary artery endothelial and vascular smooth muscle cells that may further
support the involvement of A2A and A2BARs in the regulation of CF and a further possible
interaction between these two receptor subtypes (53, 71). Coexpression of more than one
AR subtype is also reported from other laboratories on human endothelial cells (36, 53)
however, there are no reports studying whether the coexpressed receptors interact. We
have recently shown an up-regulation of A2BAR in A2AKO mouse coronary artery
suggesting an interrelationship between A2A and A2BARs subtypes since A2BAR
compensated for the down-regulation/deletion of A2AAR (69). Additionally, since the
involvement of A2A and A2BARs and their down- or up-regulation is reported in many
pathophysiological conditions (2, 40) and differential expression of ARs contributes to
functional heterogeneity of human endothelial cells (21), elucidating the presence of such
compensatory mechanisms and signaling pathways for ARs is essential for better
understanding of the heterogeneity of vascular responses and the regulation of CF.
While A2BAR is reported to induce its cardiovascular effects through activation of
arachidonic acid pathway in vasculature (13), A2AAR-induced vascular effects are
demonstrated to partly involve CYP expoxygenases (50). We and others have previously
demonstrated that A2AAR-induced vasodilation is partly due to release of nitric oxide in
mouse aorta and coronary arteries (69). However, A2BAR-induced vasodilation is both
nitric oxide-dependent and –independent in mouse aortic conduit artery and coronary
arteries, respectively (1, 69). Although KATP channels are shown to be present in coronary
artery cells (28, 65) and K+ channels in general are known to be involved in A2A and
A2BARs-mediated hyperpolarization of coronary arteries (31, 39, 52), the involvement of
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KATP channels in adenosine-induced coronary artery responses remains poorly
understood.
The purpose of the present study was to directly and more fully elucidate the
individual contribution of A2BAR and its relationship to A2AAR in A2ARs-mediated
induction of coronary artery vasodilation in light of the KATP channel involvement. The
hypotheses to be tested were; a) A2BAR contributes to coronary vasodilation, b) A2A and
A2BARs interact to induce coronary artery vasodilation and they each compensate for the
deletion/down-regulation of the other, and c) A2A and A2BARs-induced increase in CF is
the result of activation of KATP channels. Since there are inconsistencies between the
results obtained from transgenic models compared to those obtained using
pharmacological approaches (55), in this study, we have used both pharmacological and
molecular (targeted gene deleted mouse model) approaches. Furthermore, we used
A2A/2BDKO mice to remove any possible compensatory up-regulation of either A2A or
A2BAR in CF responses.

Methods
All experimental protocols were performed according to the West Virginia
University guidelines and approval of Animal Care and Use Committee.
Generation of DKO mice. A2A -/- mice (backcrossed 12 generations to the C57BL/6

background) were bred with A2B -/- mice (backcrossed 12 generations to the C57BL/6
background) to generate A2A +/- A2B +/- double heterozygotes. These double
heterozygotes were then intercrossed, and 1/16 of the resultant offspring were A2A -/-A2B
-/- DKOs. Male and female DKO breeding pairs were established from these animals to
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produce DKO mice. Since both A2A -/- and A2B -/- mice were inbred on C57BL/6, DKO
are also inbred.
WT, A2A, and A2BKO and A2A/2BDKO mice. Hearts were isolated from age-matched
10 to 14 weeks old mice. WT mice of a mixed C57BL/6 genetic background were
purchased from The Jackson Laboratory (Bar Harbor, Maine). A2BKO and A2A/2BDKO
mice of the same background were generously provided by Dr. Stephen Tilley,
Department of Medicine, University of North Carolina, Chapel Hill, NC. A2AKO mice of
the same background were generously provided by Dr. Catherine Ledent, Universite
Libre de Bruxelles, Brussels, Belgium. All four strains were bred at the West Virginia
University animal facility as a sub-colony of the original strain. The mice were kept in
cages with 12:12-hr light-dark cycles and maintained on a standard laboratory diet with
access to water ad libitum. All animal care and experimentation were in accordance with
the West Virginia University Institutional Animal Care and Use Committee and the
principles of the National Institutes of Health “Guide for the Care and Use of Laboratory
Animals.”
Chemicals. All chemicals were prepared as 10 mM stock using Dimethyl
Sulfoxide (DMSO, Sigma) followed by serial dilution with 50% DMSO and distilled
water and further dilution to desired concentration was achieved with distilled water
(final DMSO concentration of < 1%).

NECA (5'-N-ethylcarboxamido adenosine),

CGS21680, 5-hydroxydecanoate, and glibenclamide were bought from Sigma (St. Louis,
MO, USA) and SCH58261 was a gift from Schering-Plough, Italy. A2B agonist, BAY606583, was a gift from Bayer (Germany). All stated concentrations are the actual drug
concentration delivered as 1% of coronary flow.
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Langendorff-perfused mouse heart preparation. Isolated heart experiments were
performed in accordance with the methods published earlier from our lab (48). In brief,
mice were anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg). A
thoracotomy was performed, and the hearts were removed into heparinized (5U/ml) icecold Kreb-Hensleit (KH) buffer. The hearts were retrogradely perfused rapidly through
the aorta cannulated with a 20-gauge, blunt-ended needle at a constant pressure of 80
mmHg with continuously gassed with 95% O2 and 5% CO2 KH buffer containing (mM):
119 NaCl, 11 Glucose, 22 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2
Pyruvate and 0.5 EDTA at 37°C in a standard Langendorff fashion and allowed to beat
spontaneously. The left atrium was removed and the left ventricle was vented with a
small polyethylene apical drain. A water-filled balloon made of plastic wrap was inserted
into the left ventricle across the mitral valve, which was connected to a fluid-filled
pressure transducer by polyethylene tubing for continuous measurement of left
ventricular developed pressure (LVDP). Left ventricle diastolic pressure was adjusted to
a pressure of 2-5 mmHg by filling up the left ventricle balloon. Coronary flow was
measured via a Transonic flow probe (Transonic Systems; Ithaca, NY) in the aortic
perfusion line. Baseline coronary flow, LVDP, and heart rate (derived from the
ventricular pressure trace) were monitored for 30 min during the equilibration period,
which were recorded on a Power Lab data acquisition system (AD Instruments;
ColoradoSpring, CO). Hearts with persistent arrhythmias or poor LVDP (<80 mmHg)
during the equilibration period were excluded from the study. To rule out the
tachyphylaxis or desensitization, at the end of each antagonist experiment, after another
washout period, a repeat infusion of the agonist was performed.
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U

Experimental Protocols. After 30 minutes of equilibrium, baseline coronary flow, heart

rate, and developed pressure were measured in WT, A2BKO, and A2A/2BDKO isolated
hearts. Concentration-response curve (CRC) (10 -10-10-6M) were performed for BAY606583 (A2B selective agonist), NECA (non-selective AR agonist) and CGS21680 (selective
A2A agonist) by infusing the drugs into the coronary perfusate through an injection port
directly proximal to the aortic cannula using a microinjection infusion pump (Harvard
Apparatus; Holliston, MA). After equilibration period, each heart was perfused with
increasing concentration of selected drug to develop a concentration-response
relationship curve. Each drug concentration was given for 5 min with 10 min intervals to
allow complete drug washout (or using recovery to baseline parameters). All
concentrations are the actual concentration in the perfusate. Data were collected at the
end of each infusion period and washout time, which was used as a reference for
normalizing responses to the subsequent drug concentration. In the result section, actual
values from CRCs (figures 1-2,4, and 6) are presented as the maximum response and
values from the use of a single drug concentration in the presence and absence of an
antagonist (Figures 5 and 7-9) are presented as the actual drug-induced effect (maximal
response minus the baseline).
U

Antagonist experiment protocol. After 30 min equilibration period and measurement of
U

baseline parameters, agonists, NECA (10-8M, in A2B KO mice, or 10-8M, in A2A KO
mice, closest concentration to the EC50 obtained from previously performed experiments)
(Figures 7 and 8), BAY60-6583 (10-7M) (Figure 9), and CGS21680 (5x10 -9M) (Figure 9),
were infused for 5 min at 1% rate of coronary flow. The plateau effect of coronary flow,
heart rate, and developed pressure were recorded and a 10 min washout interval was
allowed to reach the baseline. This was followed by infusion of antagonists, SCH58261
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(10-6M, A2A selective antagonist) (71) (Figure 5) or glibenclamide (10 -5M) (Figures 7-9),
at 1% rate of coronary flow for at least 10 min after which, the agonist was also added to
the infusion line for an additional 5 min (for a total of 15 min). The baseline at the end of
antagonist infusion was treated as the new baseline for the subsequent agonist responses.
The data at the end of the 15 min (the end of infusion of both agonists and antagonists)
were used to compare with data obtained from the first infusion of the agonist alone. At
the end of the experiment, after at least 10 min of washout and reaching the baseline, the
agonist was again infused in order to check for tachyphylaxis or desensitization.
Western Blot. Mouse mesenteric arterioles (up to third branch arterioles)
homogenates were obtained from isolated and cleaned tissue using ice-cold lysis buffer
consisting of 0.05 M Tris-buffered saline, pH 7.4, 1% Triton X-100, 0.25% sodium
deoxycholate, 150 mM sodium chloride, 1 mM EDTA, 1 mM phenylmethylsulfonyl and
Halt Protease Inhibitor Cocktail (Thermo Scientific) by way of glass homogenizer.
Samples were then centrifuged for 15 min at 13,000 rpm and the supernatant was stored
at -80°C. Protein extracts (30 μg protein per well) were separated on NuPAGE 4-12%
Bis-Tris Gels (Invitrogen) along with Novex Sharp Protein Standard, 3.5–260-kDa,
(Invitrogen) run in parallel.

Proteins were then transferred to a PVDF membrane

(Millipore), blocked in 5% milk for 1 hour and then probed with anti-A2AAR Rabbit
Polyclonal IgG antibody (45) developed in our laboratory for detection of A2AAR protein
with a dilution of 1:1000 in TBST + 0.5% milk overnight at 4°C or with anti-β-actin
(Santa Cruz Biotechnology) at a dilution of 1:5000 at room temperature for 1 hour. This
was followed by incubation with a secondary horseradish peroxidase-conjugated
antibody (anti-mouse and anti-rabbit immunoglobulins, respectively; Santa Cruz
Biotechnology Inc.) for 1 h at room temperature. For detection of bands, the membranes
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were treated with an enhanced chemiluminescence reagent (GE Healthcare) for 1 min and
subsequently exposed to ECL Hyperfilm (GE Healthcare). Relative band intensities were
quantified by densitometry, and each sample was normalized to the β-actin values and
calibrated to A2AAR protein expression in WT.
Data and Statistical analysis. Western blot data and baseline functional data of
A2AKO, A2BKO, and A2A/2BDKO groups were compared to WT, analyzed by using t-test.
Differences in dose response curves and responses to each drug at the same concentration
between WT, A2BKO, A2AKO, and A2A/2BDKO hearts were analyzed using two-way
ANOVA for repeated measures. Antagonist-induced responses (HR, LVDP, and CF) for
WT, A2AKO, and A2BKO hearts were compared with t-test. Statistical comparisons were
done on percent changes. Results were considered significant when P < 0.05. Values are
means ±SEM. The EC50s were calculated using Prism (Graphpad Software, La Jolla,
CA).

Results
Baseline function in WT, A2AKO, A2BKO, and A2A/2BDKO isolated hearts. Table 1
demonstrates the baseline parameters for coronary flow (CF), heart rate (HR), and left
ventricle developed pressure (LVDP) for A2AKO, A2BKO, A2A/2BDKO, and WT mice
after 30 min of equilibration of the isolated hearts as mentioned in the “materials and
methods”. The average body weight of A2BKO mice was significantly lower compared to
the WT while heart weight to body weight ratio were not significantly different in any
KOs compared to WT. Furthermore, no significant baseline differences were observed in
CF and HR in any of the KOs compared to WT while LVDP was significantly higher in
A2A/2BDKO compared to WT hearts (Table 1).
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Effect of A2BAR activation on coronary flow. BAY60-6583 (A2B selective agonist)
caused a concentration-dependent increase in CF in WT whereas no effect was observed
in A2BKO mice (Figure 1A). BAY60-6583 increased the CF in WT mice (with a
maximum of 23.3±9ml/min/g, n=7) to a significantly higher degree compared to A2BKO
(no response) (Figure 1A). BAY60-6583 had no effect on HR of either WT or A2BKO
(Figure 1B) while it induced a significant increase in LVDP from baseline in the WT
animals to a maximum of 95.6±14.9 mmHg (Figure 1C, n=7). BAY60-6583 had no effect
on LVDP in A2BKO hearts (Figure 1C).
Contribution of A2AAR in ARs-mediated coronary vasodilation of A2BKO mice.
Since we wanted to test if A2AAR compensates for A2BAR in producing coronary
vasodilation in A2BKO mice, we used NECA (non-selective AR agonist) in A2BKO and
WT mice. NECA increased the CF in A2BKO mice (with a maximum of
34.6±4.7ml/min/g, n=8, and EC50: 6.8x10-9±0.8M) to a significantly higher degree
compared to WT mice (with a maximum of 23.1±2.1ml/min/g, n=9, and EC50: 3.5x109

±0.6M) (Figure 2A). Furthermore, NECA induced a significant increase in LVDP of

A2BKO compared to WT with a maximum increase of 115.5±8.5mmHg and
77.5±11.6mmHg, respectively (Figure 2C), while a decrease in HR was noted in both
WT and A2BKO mice with no significant difference between the two groups (Figures
2B).
Up-regulation of A2AAR expression in A2BKO isolated mesenteric arterioles. We
used mesenteric arterioles as resistance vessels to analyze A2AAR expression level in
A2BKO mice. The A2AAR protein was significantly increased in A2BKO isolated
mesenteric arterioles compared to WT (25.7% higher expression, Figure 3, n=4, p<0.05)
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Up-regulation of A2AAR in A2BKO mice. CGS21680 increased the CF (ml/min/g)
in A2BKO mice (27.2±2.6 at 5x10 -8M and 29±1.9 at 10-7M with EC50: 3.9x10-9±0.7M,
n=7) to a significantly higher degree compared to WT (22.4±1.5 at 5x10 -8M and 25.1±2.3
at 10-7M with EC50: 2.6x10-9±0.7M, n=7) (Figure 4A). Additionally, CGS21680 caused a
significant increase in LVDP (mmHg) in A2BKO (111.5±6.7 at 5x10-8M and 113±8.1 at
5x10-7M) compared to WT (97.9±4.9 at 5x10-8 M and 93±6.1 at 5x10-7M) while there
were no difference between the HR induced by CGS21680 when comparing WT and
A2BKO (Figures 4B-C).
Up-regulation of A2AAR in A2BKO mice. To further confirm the up-regulation of
A2AAR in A2BKO mice as a compensatory response for the regulation of CF, we used
SCH58261, A2A selective antagonist, and tested its effect on NECA (10 nM)-induced
increase in CF in WT and A2BKO. SCH58261 (1 µM) significantly decreased the
baseline CF (ml/min/g) of WT (from 9.9±0.7 to 6.8±0.7) and A2BKO (from 12.3±0.6 to
7.7±1.1, (Figure 5A). SCH58261 also caused a significantly higher inhibition of NECAinduced increase in CF (ml/min/g) in A2BKO (19.3±1.6 vs. 0.5±0.4 n=4) compared to WT
(19±3.5 vs. 3.6±0.5, n=6) (Figure 5A). NECA at 10 nM concentration and SCH58261
had no significant effect on HR in both WT and A2BKO animals (Figure 5B). However,
NECA significantly increased the LVDP (mmHg) in both A2BKO (from 99.9±11.5 to
141±20.8, n=4) and WT (from 89.5±4.4 to 123.1±4.5, n=6) hearts (Figure 5C).
SCH58261 significantly reduced the baseline LVDP (mmHg) in both A2BKO (from
99.9±11.6 to 84.2±12.2) and WT (from 89.5±4.4 to 80.6±5.2) hearts. Additionally,
SCH58261 significantly reduced the NECA-induced increase in LVDP in both A2BKO
and WT groups (34.9±5.9 vs. 2.8±1.5, n=4, and 33.6±5.7vs. 6.7±4, n=4, respectively)
compared to their respective controls (Figure 5C).
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Involvement of A2A and A2BARs in producing coronary vasodilation. In order to
rule out the compensatory response between A2A and A2BARs, NECA was used in
A2A/2BDKO mice (Figure 6). NECA did not induce any increase in CF in A2A/2BDKO
(n=5) while a concentration-dependent response was observed in WT with a maximum
increase up to 23.1±2.1ml/min/g (n=9) (Figure 6A). Additionally, NECA-induced effect
on LVDP (mmHg) was significantly lower in A2A/2B DKO (53±2 at 10-7M and
EC50:1.3x10-8±0.4) compared to WT (82.5±11.6 at 10-7M and EC50:1.8x10-8±0.2) (Figure
6C). However, the decrease in HR in WT was not different compared to A2A/2BDKO
hearts (Figure 6B).
Involvement of KATP channels in A2A and A2B ARs-induced increase in coronary
flow. We used 5-hydroxydecanote (mitochondrial KATP channel blocker, 10 -4M) to test its
effect on NECA (10-8M)-induced increase in CF in WT mice. The NECA concentrations
were chosen based on the EC50 obtained from previously performed experiments (10 -8M
in WT and A2BKO and 5x10-8M in A2AKO). 5-hydroxydecanote had no effect on NECAinduced increase in CF (ml/min/g) (15.3±2.8 vs. 18.5±3.1, n=5, Figure 7A). Additionally,
5-hydroxydecanote had no effect on NECA-induced changes in HR and LVDP (Figures
7B-C). Furthermore, we used glibenclamide (KATP channel blocker) to test its effect on
NECA-induced increase in CF in WT, A2A and A2BKO mice (Figures 7A and 8A).
Glibenclamide significantly reduced NECA-induced increase in CF (ml/min/g) in WT
(17.6±2 vs. 0.7±0.7, n=4, Figure 7A), A2AKO (12.5±2.3 vs. 2.3±1.1, n=5, Figure 8A), and
A2BKO (16.2±0.8 vs. 0.9±0.4, n=5, Figure 8A). However, glibenclamide did not change
NECA-induced effect on HR (bpm) in A2A and A2BKO while it significantly reduced the
NECA-induced effect on HR in WT compared to its control (28.5±9.7 vs. -8.1±7.6)
where it also significantly reduced the basal HR from 315.5±11.1 to 236.6±15.2 (Figures
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7B and 8B). Furthermore, glibenclamide did not change NECA-induced effect on LVDP
in A2AKO while significantly reduced the LVDP (mmHg) in WT (26.4±9.9 vs. 1.2±3.6)
and A2BKO (16.7±3.3 vs. 2.4±2.3, n=5) (Figures 7C and 8C). To confirm the effect of
glibenclamide we tested its effect on pinacidil (KATP channel opener as positive control).
Glibenclamide significantly reduced pinacidil-induced increase in CF (ml/min/g) from
baseline in WT (19±3 vs. 10.2±1.8, n=6). However, glibenclamide did not change
pinacidil-induced effect on HR and LVDP in WT mice (Figure 7).
Additionally, we tested the effect of glibenclamide on CGS21680 (A2A selective
agonist) and BAY60-6583(A2B selective agonist)-induced increase in CF in WT (Figure
9A). Glibenclamide significantly reduced the effect of CGS21680 (5x10 -9M) (22±2.3,
n=5) and BAY60-6583 (10-7M) (16.4±1.6, n=4) on CF (ml/min/g) to 1.2±0.4 (n=5) and
1.8±1.2 (n=4), respectively (Figure 9A). In the presence of glibenclamide both the
baseline and drug-induced effects on HR were significantly decreased compared to their
control (Figure 9B). Additionally, glibenclamide significantly reduced CGS21680 and
BAY-induced increase in LVDP (mmHg), 31.6±13.1 vs. 1.9±4.7 (n=5) and 20.1±1.7 vs.
7.7±5.5 (n=4), respectively (Figure 9C).
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Figure 3.1 Effect of BAY 60-6583 (BAY) in A2BKO and WT mice on coronary flow
(A), heart rate (B) and LVDP (left ventricle developed pressure) (C). *Significant
difference compared to WT, p<0.05.
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Figure 3.2 Effect of NECA in A2BKO and WT mice on coronary flow (A), heart rate
(B), and LVDP (C). *Significant difference compared to WT, p<0.05.
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Figure 3.3 A2AAR expression levels in WT and A2BKO isolated mesenrteric
arterioles.*Significant difference compared to WT, p<0.05.
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Figure 3.4 Effect of CGS 21680 in A2BKO and WT mice on coronary flow (A), heart
rate (B), and LVDP (C).*Significant difference compared to WT, p<0.05.
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Figure 3.5 Effect of SCH 58261(1µM) on NECA-induced increase in coronary flow
(A), heart rate (B), and LVDP (C) in WT and A2BKO. *Significant difference
between drug-induced effects in the presence of antagonist compared to their
#

corresponding control.

Significant difference in baselines in the presence of

antagonist compared to their corresponding control. $Significant difference between
WT and A2BKO antagonist treated groups, p<0.05.
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Figure 3.6 Effect of NECA in A2A/2BDKO and WT mice on coronary flow (A), heart
rate (B), and LVDP (C). *Significant difference compared to WT, p<0.05.
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Figure 3.7 Effect of 5-hydroxydecanote (5-HD) on NECA-induced increase in
coronary flow (A), heart rate (B), and LVDP (C) in WT and the effect of
glibenclamide (GB) on NECA and pinacidil (PIN)-induced increase in coronary flow
(A), heart rate (B), and LVDP (C) in WT.*Significant difference in drug-induced
effects in the presence of antagonist compared to their corresponding control.
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Significant difference in baselines in the presence of antagonist compared to their

corresponding control, p<0.05.
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Figure 3.8 Effect of glibenclamide (GB) on NECA-induced increase in coronary flow
(A), heart rate (B), and LVDP (C) in A2A KO and A2B KO. *Significant difference in
drug-induced effects in the presence of antagonist compared to their corresponding
control, p<0.05.
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Figure 3.9 Effect of glibenclamide (GB) on CGS 21680 (CGS) and BAY 60-6583
(BAY)-induced increase in coronary flow (A), heart rate (B), and LVDP (C) in WT.
*Significant difference in drug-induced effects in the presence of antagonist
compared to their corresponding control. #Significant difference in baselines in the
presence of antagonist compared to their corresponding control, p<0.05.
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Table 3.1
Baseline data for WT, A2AKO, A2BKO, and A2A/2BDKO mice hearts.
Wild-Type

A2AKO

A2BKO

A2A/2BDKO

n=30

n=12

n=29

n=15

Body weight, g

25±0.6

25±1.2

23.8±0.6*

24.7±1.1

Heart weight, g

0.1

0.1

0.1

0.1

Heart-to-body

0.5±0.4

0.4

0.4±0.1

0.4

15.2±0.8

17.2±0.9

14.5±0.7

15.6±1.8

341.6±10.3

356.8±14.5

345.1±7.8

330.4±17.8

80.3±4.2

81.2±4.8

83.3±3.3

97.1±6.2*

weight ratio, %
Coronary

flow,

ml.min-1.g-1
Heart

rate,

beats/min
Developed
pressure, mmHg

All parameters were collected after 30 min of equilibration in langendorff preparation.
All values are means± S.E.M.* significantly different compared to WT.
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Discussion
In this study we have further elucidated the contribution of A2BAR and its
relationship to A2AAR in A2 ARs-mediated coronary artery vasodilation. With the use of
A2A/2BDKO mice, we also showed for the first time that A2A and A2BARs, out of four
ARs subtypes, contribute to coronary artery vasodilation and down-regulation/deletion of
either of A2A and A2BARs leads to a compensatory up-regulation of the other AR and
thus, suggesting an interrelationship between these two receptor subtypes. Furthermore,
we showed for the first time the involvement of non-mitochondrial KATP channels in
A2BAR-mediated coronary artery vasodilation, and finally showed the direct involvement
of KATP channels in A2AAR-mediated increase in coronary flow using AR KO mice.
Adenosine’s role in tissue protection may involve mechanisms such as increasing
the tissue blood flow and protecting against ischemic damage (37). Adenosine is well
known to play a vasoregulatory role in human coronary arteries (16-17, 62-63). We and
others have previously also demonstrated the pivotal role for A2AAR in CF regulation (5,
63, 67, 69). We also have preliminary data showing the involvement of A2 AR in
coronary reactive hyperemia that indirectly supports a physiological role for adenosine in
CF regulation (data not shown) which is in support of previous in vivo and ex vivo
reactive hyperemia studies (5, 12, 77). Additionally, it is suggested that A2AAR activation
contributes to basal tone in coronary circulation through the release of nitric oxide (69).
Our present data (Figure 5A) also support such a role for A2AAR since SCH58261
(A2AAR selective antagonist) significantly reduced the baseline CF.
Due to its low affinity for adenosine, A2BAR is known to be activated in
conditions where a significant increase in adenosine levels is observed, such as in
ischemic conditions (25). Therefore, A2BAR may be more involved in pathophysiological
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conditions rather than physiological situations. However, cardiovascular effects of
A2BAR and its role in coronary vasodilation still remain to be fully elucidated. It was
reported that A2BAR plays a role in ischemia/reperfusion and preconditioning (15).
Additionally, previous studies have used indirect measures such as non-selective
agonist/antagonist (alloxazine), which is only about 10 fold more selective towards
A2BAR relative to A2AAR (8), or A2AKO mice (without the use of A2B knockout) to
indirectly study the role of A2BAR in CF regulation (48, 67). In this study, we
demonstrated the contribution of both A2A and A2BARs in coronary artery vasodilation
where we further clarified the individual role of A2BAR with the use of selective A2BAR
agonist BAY 60-6583 and A2BKO mice (Figure 1). We also demonstrated that A2A and
A2BARs, out of all ARs, are involved in inducing coronary artery vasodilation with the
use of A2A/2BDKO mice (Figure 6). Reports suggesting that A1 and A3 ARs negatively
modulate the role of A2A and A2BARs in CF regulation (66, 68) and the presence of only
A2A and A2BARs on human and porcine coronary endothelial cells (53) may also
indirectly support their involvement in coronary artery vasodilation.
Azakura et. al. suggested that the impairment of adenosine-related signaling
contributes to the pathophysiology of congestive heart failure (2). In addition, we have
previously demonstrated that A2AAR is up-regulated in high-salt compared to normal-salt
fed mice (51) and failure to up-regulate A2AAR-induced pathway contributes to the
development of hypertension (44). Furthermore, few studies have shown that A2BAR is
selectively up-regulated in ischemic mouse hearts and by hypoxic conditions (3, 18) and
differential expression of ARs contributes to functional heterogeneity of human
endothelial cells (21). We have recently shown the up-regulation of A2BAR in A2AKO
mice (69) and in this current study we demonstrated the up-regulation of A2AAR in
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A2BKO mice (Figures 2-5), suggesting the presence of a relationship between these two
ARs. Therefore, further understanding of the relationship between A2A and A2BARs may
help us towards development of newer therapeutic approaches. Also, the observation that
the down-regulation/deletion of A2A or A2BAR leads to compensatory up-regulation of
A2B and A2AAR, respectively, itself supports an important regulatory function for each of
these AR subtypes. It is interesting to mention that this trend is observed in hypoxia of
human umbilical vein endothelial and bronchial smooth muscle cells where hypoxia
modulates the expression of ARs by decreasing A2AAR mRNA but increasing A2BAR
mRNA levels (22). It is also noteworthy to mention that adenosine acts as a feed-back
mediator in heart during hypertrophy and hypoxia (34) during which conditions other
studies have shown the modification of ARs’ expression (2-3, 18, 22). These kinds of
interactions have also been observed between other receptor subtypes such as
adrenoceptors (ADR), where α1ADR compensates for the down-regulation of βADR in
pathological conditions such as cardiac remodeling (75).
Adenosine and its agonist are currently being used in clinical settings; The
vasoregulatory properties of ARs are used clinically in humans for the diagnosis of
coronary artery disease through the use of Adenosine (Adenoscan) as a substitute for
exercise stress testing in myocardial perfusion imaging (7). The use of Adenoscan has its
own limitations due to it blocking the AV conduction (due to activation of A1 AR (4, 7))
and inducing bronchospasm (probably due to activation of A1, A3 or A2BARs (24, 59)).
However, these side effects may be alleviated by the development of more A2 AR subtype
selective agonists. A new A2AAR selective agonist called Regadenoson (Lexiscan®) has
been developed and approved by FDA which is being used clinically in myocardial
perfusion imaging. During this use of adenosine and its agonist in determining coronary
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reserve, the assessment of the true maximal dilatation of coronary arteries is an important
factor (34). However, it is reported that maximal dilatation of coronary arteries with
vasodilators such as adenosine does not eliminate all coronary vasomotor tone and that
the role of hemodynamic changes should also be considered (34, 73). Nevertheless, the
knowledge of the presence of a compensatory interaction between A2A and A2BARs may
be helpful since most cardiac imagings are done in patients with vascular disease where
the AR expression may have been already modified due to the disease condition.
Furthermore, adenosine is being investigated as a treatment during percutaneous coronary
intervention in order to reduce the myocardial reperfusion injury in patients with
myocardial infarction (which is usually associated with worsening of cardiac injury and
function). In these patients, intracoronary injection of adenosine is followed by a better
myocardial salvage and thus prevention of left ventricular remodeling, ejection fraction,
decreased infarct size, and ST-segment elevation resolution (10, 26, 46). However,
Desmet et. al. demonstrated that adenosine significantly ameliorates ST-segment
resolution while it does not improve myocardial salvage or coronary blood flow (11).
Additionally, in another study, Ross et. al. showed a relationship between infarct size and
primary clinical end point (death or heart failure) where adenosine significantly reduced
the infarct size while, it did not improve the clinical outcome (61).
It is well known that arterioles, compared to coronary conduit arteries, are the
major players in flow regulation and as previously reported, A2AAR may be the major
coronary artery vasodilator compared to A2BAR. Furthermore, large coronary arterioles
were shown to be less responsive to adenosine than small ones and Hein et. al. have
reported that mainly A2AARs are expressed in coronary arterioles (32, 42). The same
disparity of receptor subtype distribution has also been seen with adrenoceptors, with
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adrenergic constriction of large arterioles being mediated by α 1 while in terminal
arterioles α2 exert this function (56). Additionally, in coronary arterioles, a greater α2
response has been shown compared to larger coronary arteries (70). Thus, showing the
up-regulation of A2AAR in A2BKO mice would most likely not be reflected on larger
coronary conduit arteries such as LAD. Isolation of mouse LAD and other large coronary
conduit arteries is technically difficult but possible, however isolation of coronary
resistance arterioles from mouse heart is almost impossible and to our knowledge no one
has been able to isolate coronary arterioles so far which is a limitation in our study.
However, A2AAR protein expression in mouse mesenteric artery resistance vessels (up to
third branch of arterioles) shows the up-regulation of A2AAR in A2BKO mice which
confirms the compensatory up-regulation of A2AAR in A2BKO mice resistance vessels
(Figure 3).
The occurrence of the up-regulatory mechanism phenomenon in our studies may
be TNF-α-induced and post-transcriptionally regulated (41) or due to DNA methylation
since this may regulate AR cell surface expression levels (9). Furthermore, HIF-1 has
also been suggested to up-regulate the expression of A2BAR in hypoxic conditions (76).
Although, the underlying mechanism may not be understood at this time, it seems that
this relationship only exists between A2A and A2BARs and not between A1 or A3 ARs
since there was no significant difference between the concentration response curve for
CCPA (A1AR selective agonist) and Cl-IBMECA (A3 AR selective agonist) in
A2A/2BDKO mice compared to WT (data not shown).
Potassium channels have been suggested to be involved in regulating blood flow
and blood pressure and in AR signaling pathways (29, 49, 78). For example, inward
rectifier K+ (KIR) channels may play a role since their presence has been reported on
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coronary artery smooth muscle cells (CASMCs) (54, 60, 65), in addition, to their role as
the dominant K+ conductance in resting membrane potential (38). Moreover, adenosine is
reported to activate ATP-sensitive potassium (KATP) channels in rabbit mesenteric
arteries and isolated CASMCs (58, 65). Others have demonstrated the presence of KATP
channels on coronary arteries and CASMCs (28, 65) and their role in A2A-induced effect
in reactive hyperemia and retinal microvessels dilation (5, 33, 77). However there are no
reports to our knowledge suggesting the involvement of KATP channels in A2A and
A2BARs-induced changes in mouse CF.
In this study, we used mitochondrial KATP channel blocker, 5-hydroxydeconoate
(5-HD) and glibenclamide to test KATP channels involvement in A2A and A2BARs-induced
CF changes. Glibenclamide blocked the NECA-induced increase in CF in A2A and
A2BKO and BAY60-6583-, and CGS21680-induced increase in CF in WT mice.
However, 5-HD had no effect on NECA-induced increase in CF, which may suggest a
role for non-mitochondrial KATP channels in both A2A and A2BARs signaling pathways
(Figures 7-9A). However, this study does not show if the KATP channels are located on
endothelial or SMCs. This is important since endothelial dysfunction is an early risk
factor for cardiovascular diseases where a reduced adenosine response has been reported
(19). Further, Wang et. al. suggested that activation of endothelial KATP channels might
result in the protection against endothelial dysfunction (74). We think that adenosineinduced activation of KATP channels may be indirectly through release of some other
mediators such as hydrogen peroxide (27), which was previously suggested to be the
endothelium-derived hyperpolarizing factor (47) and that may be involved in
cardiovascular dysfunction (64). Elucidations of these signaling pathways will help us
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better understand the underlying cause of reduced adenosine response in cardiovascular
diseases.
The availability of gene deleted knockout mice has been an important tool to
dissect the physiological and pharmacological pathways for elucidating the role of a
single receptor. However, in some instances, mice lacking a specific receptor gene
exhibit phenotypic differences such as higher blood pressure in A2AKO mice (43).
Therefore, in this study we used both pharmacological and molecular (single and double
gene knockout) approaches to confirm our results. We also evaluated the baseline
parameters of WT and KO hearts (Table 1). The baseline LVDP of A2A/2BDKO was
significantly higher compared to WT, which may be attributed to alterations at second
messenger or translational levels. The relationship between A2A and A2BARs and
activation of other signaling pathways such as an increase in the levels of cAMP and Ca 2+
may compensate for the deletion of A2A/2BARs (35, 37). Even adrenoceptors may
compensate for the absence of A2A and A2BARs since there are reports showing direct and
indirect anti β-adrenergic effect of adenosine, suggesting the presence of an interaction
between these two different GPCRs (49). Further experiments are required to better
understand the relationship between these two receptor classes. There are no significant
differences in baseline HR, LVDP, and CF of A2AKO and A2BKO mice compared to WT.
We also tested the A2BKO mice for endothelium functionality using bradykinin where we
found no significant difference between the A2BKO and WT groups, thus, showing the
presence of a normal functional endothelium in A2BKO (data not shown).
CGS21680 and NECA induced an increase in LVDP of WT and A2BKO but not
A2A/2BDKO. BAY60-6583 also induced an increase in LVDP of WT mice. These data
support our previous report that A2A and A2BARs may be involved in cardiac contractility
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and positive inotropic effect (Figures 1, 2, and 4C) (69). Changes in CF can affect the
contractility (Gregg effect) which is an inherent problem with the isolated perfused heart
preparation. However, as shown in this study (Figures 2 and 6), the increase in CF comes
earlier than the changes in LVDP which may suggest that the observed effects of A2 ARs
activation on LVDP may not be due to Gregg’s effect. The opening of K ATP channels
may also affect the contractility independent of CF changes which may be independent of
non-mitochondrial KATP channels in this study since there is no difference observed in
NECA-induced changes in LVDP in the presence of 5-HD (mitochondrial KATP channel
blocker) while a significant decrease in NECA-induced changes in LVDP was shown in
the presence of glibenclamide (non-selective KATP channel blocker) (Figure 7).
Additional studies are needed to define the role of A2 ARs on LVDP. However, our data
from A2A/2BDKO are very important since they show that only A2A and A2BARs are
involved in LVDP and coronary vasodilation which could be further exploited for
therapeutic approaches such as heart failure.
Our current study also confirms our previous finding that A1 AR plays a role in
HR (68) while A2A and A2BARs do not since BAY60-6583 (Figure 1B) and CGS21680
(Figure 4B) did not affect HR while NECA (non-selective agonist) decreased the HR
(Figure 2B). Additionally, our data showed a decrease in baseline HR in the presence of
glibenclamide (Figures 7 and 9B) which could be due to the presence of K ATP channels
on atria and ventricle (79) and the KATP channel-dependent potassium efflux-induced
shortening of cardiac action potentials and hence a decrease in HR (79).
In conclusion, we showed for the first time, the individual role of A2BAR and the
contribution of A2AAR in A2 ARs-mediated coronary vasodilation using A2BKO and
A2A/2BDKO mice along with the use of A2BAR and A2AAR selective agonists. We found
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that A2A and A2BARs contribute to coronary artery vasodilation which involves KATP
channels and that A2AAR is up-regulated in A2BKO mice. These findings are another step
toward a better understanding of ARs’ pharmacology in coronary artery and the
heterogeneity of CF responses by ARs which may lead to better therapeutic approaches
for the treatment of cardiovascular disorders.
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CHAPTER FOUR

Interactions between A2A adenosine receptor, hydrogen peroxide, and K+-ATP
channel in coronary reactive hyperemia
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Abstract
Myocardial metabolites such as adenosine mediate reactive hyperemia (RH), partially, by
activating ATP-dependent K+ (KATP) channels in coronary smooth muscle. In this study, we
investigated the role of A2 adenosine receptors (ARs) and their downstream signaling
mechanisms in RH. We tested the hypothesis that coronary RH involves A 2AARs, hydrogen
peroxide (H2O2), and KATP channels using A2A and A2B single (KO) and A2A/2B double knockout
(DKO) mice hearts in a Langendorff heart. Flow debt-to-repayment ratio (RPA//DA) following a
15s occlusion was 1.3±0.1 in WT which was reduced in hearts from A2AKO (0.9±0.1), but not
A2BKO (1.2±0.1) mice. Catalase (1250 U/ml), an enzyme that breaks down H 2O2, significantly
reduced the baseline flow (ml/min/g) in A2AKO hearts (16.8±0.9) compared with control
(19.4±1.6) and WT in the presence and absence of catalase (21.4±2.1 and 19.8±0.9, respectively).
However, catalase significantly reduced the RPA/DA in WT (0.8±0.1) but, not in A2AKO
(0.9±0.1) mice compared with its control. Patch clamp experiments demonstrated that adenosine
(10μM) activated a glibenclamide (10μM; a KATP channel blocker)-sensitive conductance (nS/pF)
in smooth muscle cells from WT (0.048±0.01) but not A2A/A2BDKO (0.016±0.01) mice.
Importantly, however, conductance activated by pinacidil (10 μM; a KATP channel opener) was
similar in cells from WT and A2A/A2BDKO mice (0.013±0.034 vs. 0.012±0.04 nS/pF).
Additionally, in WT smooth muscle cells, H2O2 (1 mmol/L) activated a glibenclamide-sensitive
conductance (0.074±0.02 nS/pF). Our data indicate that A2AARs are coupled to KATP channels in
RH, in part, via the production of H2O2 as a signaling intermediate.

Keywords: coronary circulation, ischemic vasodilation, adenosine receptors, knockout mice,
reactive oxygen species
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Introduction
The heart responds to acute ischemia by transiently increasing blood flow in a
phenomenon called reactive hyperemia (RH) (7). The temporary reduction in coronary vascular
resistance is mediated by chemical signals released into blood (47), including adenosine (44).
Adenosine induces its effects through activation of its receptors (AR) namely A1, A2A, A2B, and
A3. Adenosine’s cardiovascular effects depend on the activation of the subtype of receptor
involved, where A2ARs are known to play a role in coronary vasodilation through their action on
both endothelial and smooth muscle cells. Our laboratory and others have shown that A 2AARs
play a pivotal role in the regulation of coronary flow (CF) (48, 50), while, A2BARs are also
involved, albeit with a lesser contribution compared to A2AARs (32, 48, 50). Additionally,
pharmacological studies indicate that A2A and A2BARs are the subtypes most likely involved in
coronary RH (2, 11, 62). However, undesirable overlap in the pharmacological profiles of
adenosine receptor antagonists obfuscates the relative contribution of A 2A and A2BARs in RH.
Thus, in order to more specifically determine the roles of A2A and A2BARs in coronary RH, we
used Langendorff-perfused hearts from wild type (WT) and A2A, A2B knockout (KO) and A2A and
A2B double knockout (DKO) mice.
Numerous mediators and end effectors of coronary RH have been proposed. Importantly,
however, information remains scarce regarding the role of H2O2, a coronary metabolic and
endothelium-dependent vasodilator (29, 45, 58), and its interactions with ARs and K ATP channels.
Some support for H2O2 in RH has been provided by studies of skeletal muscle and isolated
coronary arterioles (3, 20). The idea that K ATP channels participate in coronary RH is well
established (1, 12), but it is unknown whether H2O2 couples adenosine receptor activation to K ATP
channel activity. KATP channels are known to mediate, at least in part, H2O2-induced dilatation of
arterioles from skeletal muscle and brain (25, 55) and cardiac myocytes (18). However, to our
knowledge, direct evidence of this mechanism in smooth muscle is still to be elucidated. Thus, we
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ascertained whether H2O2 is involved in coronary RH and whether H2O2 mediates the coupling of
adenosine receptors to activation of KATP in coronary RH.

Materials and Methods
Animals. An Institutional Animal Care and Use Committee at West Virginia University
School of Medicine approved all experimental protocols. We followed guidelines set forth by the
American Physiological Society and National Institutes of Health regarding the care and use of
laboratory animals. A2A and A2B knockout mice, both backcrossed 12 generations to the WT
C57BL/6 background (Jackson Laboratory; Bar Harbor, ME), were bred to generate A 2A/A2B
double heterozygotes. Double heterozygotes were intercrossed, 1/16 of the offspring were
A2A/A2B double knockouts, and A2A/A2B knockout breeding pairs were established. Mice were
caged in a 12:12-hr light-dark cycle with free access to standard chow and water.
WT, A2A, and A2BKO and A2A/2BDKO mice. WT mice of a mixed C57/BL6 genetic
background were purchased from The Jackson Laboratory (Bar Harbor, Maine). All four WT,
A2AKO, A2BKO, and A2A/2BDKO strains were bred at the West Virginia University animal facility
as a sub-colony of the original strain. All animal care and experimentation were in accordance
with the West Virginia University Institutional Animal Care and Use Committee and the
principles of the National Institutes of Health “Guide for the Care and Use of Laboratory
Animals.”
Langendorff-perfusion. Mice (10-14 wks of age) were anesthetized with sodium
pentobarbital (50 mg/kg i.p.) and hearts were excised into heparinized (5 U/ml) ice-cold KrebsHenseleit (KH) buffer. KH contained (mmol/L) 119 NaCl, 11 glucose, 22 NaHCO3, 4.7 KCl, 1.2
KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2 pyruvate and 0.5 EDTA. Hearts beat spontaneously when
retrogradely perfused (80 mmHg) with 37°C KH bubbled with 95% O 2 and 5% CO2. The left
atrium was removed and the left ventricle drained. A fluid-filled balloon was inserted into the left
ventricle and connected to a transducer for pressure measurements. Left ventricular diastolic
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pressure was adjusted to 2-5 mmHg. Coronary flow was measured with a probe (Transonic
Systems; Ithaca, NY) in the aortic perfusion line. Hearts were paced to 400 beats/min and
function allowed to stabilize. Hearts with persistent arrhythmias or developed pressure less than
80 mmHg were excluded from the study. Baseline coronary flow and cardiac function were
measured using a Power Lab data acquisition system (AD Instruments; Colorado Springs, CO).
Hearts were then subjected to 15 seconds of total flow occlusion to elicit hyperemia. Catalase
(Sigma Chemical Co.; St. Louis, MO) was delivered into the aortic perfusion line using a
microinjection pump (Harvard Apparatus; Holliston, MA) as 1% of coronary flow to achieve a
final concentration of 1250 U/ml (57, 60).

Patch clamp. Single smooth muscle cells were enzymatically isolated from the aortas of
WT and A2A/A2B knockout mice. For cell isolation, a simple HEPES-buffered saline was used and
contained (mmol/L) 135 NaCl, 5 KCl, 1 MgCl2, 0.36 CaCl2, 10 glucose, 10 HEPES, and 5 Tris;
pH 7.4. The aorta was placed in this solution plus (mg/ml) 2 collagenase, 1 elastase, 2 bovine
serum albumin, and 1 soybean trypsin inhibitor for 15 min at 37°C. The tissue was passed
through the tip of a fire-polished Pasteur pipette to liberate single cells. Smooth muscle cells were
pelleted at 0.5 g, resuspended in enzyme-free buffer, placed on ice, and used within 8 hr. Cells
were placed in a recording chamber atop an inverted microscope and perfused with a HEPESbuffered solution (as above) containing 140 mmol/L K+. Patch pipettes (3-5 MOhms) were filled
with this 140 mmol/L K+ solution supplemented with 5 mmol/L Mg-ATP and 0.1 mM Na-GTP;
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pH 7.1. Inward KATP currents were recorded in the conventional whole-cell mode (with Nernst
equilibrium potential for K+ set to 0 mV). The membrane potential was held at -80 and ramped or
stepped to potentials between -100 and +100 mV. Currents were low-pass filtered a 1 kHz and
digitized at 5 kHz. Series resistance and whole-cell capacitance were compensated as completely
as possible using circuitry of the amplifier (PC-505, Warner Instruments; Hamden, CT). This
amplifier was interfaced to a computer with pClamp 9 software for data acquisition and analysis
(Molecular Devices; Sunnyvale, CA).
Statistical analysis. Statistical analyses were made with t-test and one- or two-way
analysis of variance (ANOVA) with post hoc tests as indicated. Results were considered
significant when P < 0.05. Values are means ± SEM from n number of animals.

Results
Involvement of A2AARs in coronary reactive hyperemia. We used WT and A2AKO mice in
order to test the involvement of A2AARs in coronary RH. The flow debt-to-repayment ratio was
significantly reduced in A2AKO (0.9±0.1, n=8) compared with WT (1.3±0.1, n=6) mice (Figure
1B) while, the peak flow was not different between the two groups (WT: 42.7±2 ml/min/g, n=6
vs. A2A KO: 42.9±1.7 ml/min/g, n=8, Figure 1C). The resting flow of 19.4± 1.6 ml/min/g (n=8) in
A2AKO was similar to WT (19.8 ± 0.9 ml/min/g, n=6, Table 1).
A2BARs may not be involved in coronary reactive hyperemia. In order to characterize the
role of A2BARs in coronary RH, we performed our RH experiments in WT and A2BKO mice. The
flow debt-to-repayment ratio (Figure 2B) and peak flow (Figure 2C) in A2BKO, 1.2±0.1 and
44.2±0.5 ml/min/g (n=4), respectively, were not different compared with WT, 1.3±0.1 and 42.7±2
ml/min/g (n=6), respectively. Additionally, the resting flow of A2BKO, 20.3±1.1 ml/min/g was
not different compared with WT, 19.8±0.9 ml/min/g, respectively (Table 1).
Involvement of only A2ARs in coronary reactive hyperemia. Since we have previously
shown that only A2A and A2BARs, out of four ARs, are involved in the regulation of CF (48), we
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tested the involvement of other ARs than A2ARs in coronary RH using WT and A2A/2BDKO mice.
The flow debt-to-repayment ratio was significantly higher in WT (1.3±0.1, n=6) compared with
A2A/2BDKO (1±0.1, n=8) mice (Figure 3B), which may be only due to the absence of A 2AARs,
nevertheless, the peak flow was not different between the two groups, 42.7±2 ml/min/g and
41.6±1.2 ml/min/g, respectively (Figure 3C). Additionally, the resting flow of A2A/2BDKO,
18.6±0.6 ml/min/g (n=8) was not different compared with WT (Table 1).
Adenosine activates KATP channels. It is known that KATP channels play a role in coronary
RH (2, 62). We have also previously reported that both A2A and A2B ARs induce coronary
vasodilation, and hence an increase in CF, through activation of KATP channels (48). We
established this finding by using our isolated heart system (48). However, in this study we wanted
to investigate this finding on a molecular level using patch clamp. Since both A 2A and A2B ARs
were shown to activate KATP channels, in this study, we used A2A/2BDKO mice in order to be able
to distinguish the currents activated due to activation of ARs. Adenosine (10μmol/L) activated a
conductance (nS/pF) sensitive to the K ATP channel blocker, glibenclamide (10μmol/L), in smooth
muscle cells from WT (0.048±0.01) but not A2A/A2BDKO (0.016±0.007) mice. Also, pinacidil (10
μmol/L; a KATP channel opener) activated the same conductance similarly in cells from both WT
and A2A/A2BDKO mice (0.013±0.034 vs. 0.012±0.04 nS/pF) (Figure 4).
Involvement of H2O2 in adenosine-induced increase in coronary flow. To test if H2O2
induces coronary vasodilation, we performed exogenous H2O2 concentration-curve. Exogenous
H2O2 significantly increased the coronary flow from baseline (from 11.3 to 38.1 ml/min/g, data
not shown). We used catalase (1250 u/ml), an enzyme which breaks down hydrogen peroxide into
water and oxygen, to test its effect on adenosine-induced increase in CF in WT mice. Catalase
significantly decreased adenosine-induced increase in CF in WT (from 30 ± 4.4 to 8.4 ± 1
ml/min.g, n=4), A2AKO (from 33.2 ± 2.3 to 9.9 ± 1 ml/min/g, n=4), and A2BKO (from 35.2 ± 1.5
to 13.4 ± 0.8 ml/min/g, n=4) mice (Figure 5A). Catalase also significantly decreased adenosineinduced changes in LVDP in WT (from 122.4 ± 11 to 78 ± 7 mmHg), A2AKO (from 119.2 ± 4.1
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to 74.6 ± 4 mmHg), and A2BKO (from 139.1 ± 6 to 81 ± 10.1 mmHg) mice while it had no effect
on HR (Figures 5 B-C).
Involvement of H2O2 in coronary reactive hyperemia. Since we showed that adenosine is
involved in coronary RH and that it induces coronary vasodilation through release of H2O2, we
wanted to test if H 2O2 itself is also involved in coronary RH. Therefore, we used catalase (1250
u/ml) in WT mice. Catalase significantly decreased the flow debt-to-repayment ratio in WT
compared with its control, 0.8±0.1 (n=6) vs. 1.3±0.1 (n=6), respectively (Figure 6B). However,
the resting flow was similar to WT in the presence of catalase (21.4±2.1 ml/min/g, n=6)
compared to its control (19.8±0.9 ml/min/g, n=6) (Table 1). Nevertheless, the peak flow in WT
mice, in the presence of catalase, (38.6±2.4 ml/min/g, n=6) was also significantly attenuated
compared to its control (42.7±2 ml/min/g, n=6) (Figure 6C).
Involvement of H2O2 in A2AR-mediatesd coronary reactive hyperemia. We used catalase
(1250 u/ml) in A2AKO mice in order to investigate the role of H2O2 in A2AAR-induced effects in
coronary RH. Catalase significantly decreased the flow debt-to-repayment ratio in A2AKO
(0.9±0.1, n=6) (Figure 7B) compared with WT in the absence of catalase (1.3±0.1, n=5) (Figures
1,2,3, and 6 B) while, it was not different compared to WT (0.8±0.1, n=6) in the presence of
catalase. Also, there was no difference between flow debt-to-repayment ratio in A2AKO in
presence of catalase (0.9±0.1, n=6) compared with A2AKO (0.9±0.1, n=8) (Figures 7B). Further
resting flow of A2AKO in the presence of catalase (16.8±0.9 ml/min/g) was significantly lower
compared with WT (19.8±0.9 ml/min/g) and A2AKO (19.4±1.6 ml/min/g) in the absence of
catalase, while there was no difference between the two latter groups (Table 1). The peak flow in
A2AKO, in the presence of catalase, (36.3±1.4 ml/min/g, n=6) (Figure 7C) was significantly lower
compared with WT (42.7±2 ml/min/g, n=6) (Figure 1C) and A2AKO (42.9±1.7 ml/min/g, n=8) in
the absence of catalase (Figure 7C); this is when the WT and A2AKO peak flow, in the presence
of catalase, were similar (Figure 1C). These findings may suggest that A 2AARs may, at least in
part, play their role in coronary RH through release of H2O2.
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H2O2 activates KATP channels. In smooth muscle cells from WT mice, H2O2 (1 mmol/L)
activated a glibenclamide-sensitive conductance (0.074±0.02 nS/pF) (Figure 8).
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Fig. 4.1 Repayment volume (B), but not resting flow (A) or peak flow (C), is reduced in
A2AKO (n=8) mice, compared with WT (n=6), in coronary RH. *Significant difference
compared with WT, p<0.05.
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Fig. 4.2 Baseline coronary flow (A), peak flow (B), and flow repayment area (C) of
coronary RH are normal in A2BKO (n=4) mice compared with WT (n=6).
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Fig. 4.3 Changes on coronary flow (A), peak flow (B), and flow repayment area (C) in WT
(n=6) and A2A/2BDKO (n=8) mice during coronary RH. *Significant difference compared
with WT, p<0.05.
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Fig. 4.4 Adenosine-induced KATP current is reduced in smooth muscle cells of A2A/2BDKO
mice. (A) Glibenclamide-sensitive conductance (nS/pF) in WT and A2A/2BDKO mice. (B)
Group data showing reduced effect of adenosine in A2A/2BDKO mice (n=4), but response to
pinacidil were not different from WT (n=5). *Significant difference compared with WT,
p<0.05.
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Fig. 4.5 Attenuated adenosine-induced increase in coronary flow (A) and LVDP (C), and
normal heart rate (B), in WT (n=4), A2AKO (n=4), and A2BKO (n=4) mice, in the presence of
catalase (Cat). *Significant difference compared to corresponding control, p<0.05.
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Fig. 4.6 Attenuated peak flow (B) and Repayment area (C), but normal baseline CF (A), in
the presence of catalase (Cat) in WT (n=6) mice. *Significant difference compared with WT,
p<0.05.
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Fig. 4.7 Reactive hyperemia-induced changes on coronary flow (A), peak flow (B), and flow
repayment area (C) in the presence (n=6) and absence (n=8) of catalase (Cat) in A 2AKO
mice.
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Fig. 4.8 H2O2 increases a glibenclamide-sensitive conductance (nS/pF) in WT smooth
muscle cells. (A) Representative trace showing effect of H 2O2 to increase KATP current. (B)
Group data (n=5 mice) illustrate effect of H2O2 relative to pinacidil. *Significant difference
compared with control, p<0.05.
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Fig. 4.9 Effect of catalase on adenosine and pinacidil mediated increase in

Normalized K ATP conductance

KATP conductance (nS/pF)

glibenclamide-sensitive conductance (nS/pF) in WT smooth muscle cells (n=5).
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Table 4.1
Resting flow, debt area (DA), peak flow, flow repayment area (RPA), and debt to repayment area
ratio (RPA/DA).
Resting
Flow
(ml/min/g)

Debt Area Peak
(DA) (ml/g) (ml/min/g)

Repayment
Area
(RPA)
(ml/g)

Debt
to
Repayment
area

WT

19.8±0.9

4.9±0.2

42.7±2

6.3±0.4

RPA/DA
1.3±0.1

A2AKO

19.4±1.6

4.9±0.4

42.9±1.7

4.5±0.2*

0.9±0.1*

A2BKO

20.3±1.1

5.1±0.3

44.2±0.5

6.1±0.1

1.2±0.1

A2A/2BKO

18.6±0.6

4.7±0.1

41.6±1.2

4.9±0.2*

1±0.1*

WT+Cat

21.4±2.1

5.3±0.5

38.6±2.4*

4.4±0.4*

0.8±0.1*

A2AKO+Cat

16.8±0.9*

4.2±0.2*

36.3±1.4*

4.1±0.4*

0.9±0.1*

All values are means ± S.E.M. * p<0.05 compared with WT
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Discussion
The new findings in this study show: 1) a better elucidation of the individual involvement
of A2AARs in RH, 2) a demonstration that H2O2 contributes to CF responses in RH, and 3) that
H2O2 couples adenosine-mediated CF responses in RH to K ATP channel activation. Using A2A and
A2BKO and A2A/2BDKO mice, we showed that only A2AAR, out of four AR subtypes, is involved
in RH. Additionally, we showed for the first time the involvement of H 2O2 in mouse coronary RH
in addition to its involvement in A2AAR-induced KATP channel activation.
Increased oxygen demand over oxygen supply ratio of the myocardium is exerted through
myocardial oxygen tension (pO2), which is decreased in ischemic conditions. This fall in pO2
leads to the breakdown of adenine nucleotides leading to the production of adenosine that is
known to mediate local metabolic control of CF (14). Previous RH studies investigating the effect
of different occlusion periods suggested that metabolic vasodilatory factors are the primary
mediators responsible for the increase in flow during RH (7, 17, 38, 39). Further, our laboratory
and others have previously shown that activation of A2A and A2B ARs induces an increase in CF
(37, 46, 49). Therefore, in this study, we wanted to test the role of adenosine, a well established
local metabolite, in CF changes in RH. The involvement of adenosine in coronary RH was
recently reported in an in vivo dog study, where the AR subtypes involved was not assessed (11).
Nevertheless, using an A2AAR selective antagonist (SCH58261), Zatta et al. reported coronary
RH responses mediated by A2AARs with a flow repayment area decrease of up to 30% and no
change in peak flow (62). Also, in a previous in vivo study in dogs, the role of A2BAR-mediated
CF changes in RH was assessed using a non-selective antagonist (alloxazine) which is only about
10 fold more selective towards A2BARs relative to A2AARs (2). Therefore, a further study was
needed in order to fully elucidate the role of ARs in coronary RH without the effect of
pharmacological changes. The availability of gene deleted knockout mice has been an important
tool to analyze the physiological and pharmacological pathways for elucidating the role of a
single receptor. Therefore, in this study, using A2A and A2BKO isolated mice hearts, we directly
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showed that A2AARs contribute to CF changes in mouse coronary RH by demonstrating a
significant decrease in flow repayment time and volume (flow repayment area) in A 2AKO mice
compared with WT. These results are in accordance with recent studies showing a role for ARs in
flow repayment area and not the peak flow (62). However, our results from A2BKO and
A2A/2BDKO mice did not suggest any role for A2BARs in CF changes in RH. Due to its low
affinity for adenosine, A2BARs are suggested to be activated in conditions where a significant
increase in adenosine levels is observed (15). For example it was reported that A2BARs play a role
in ischemia/reperfusion and preconditioning (13). Therefore, A2BARs may be more involved in
severe ischemic pathophysiological conditions such as stroke or in protective preconditioning
pathways rather than in physiological situations. Indeed, A2ARs agonists are being investigated as
a treatment during percutaneous coronary intervention for the reduction of myocardial
reperfusion injury in patients with myocardial infarction, which is well established to be
associated with worsening of cardiac injury and function (6, 10).
Berne’s adenosine hypothesis suggests that increase in myocardial oxygen consumption
decreases the myocardial oxygen tension which leads to the release of adenosine from
cardiomyocyte (53), where A2AARs have also been found to be expressed in both human and
mouse (4, 24). Furthermore, a role for H2O2 in metabolic vasodilation is already established (59).
Chilian et al. suggested that H2O2 production increases in proportion to cardiac metabolism in
order to couple the coronary blood flow to myocardial oxygen tension (45). It is interesting to
know that both H2O2 and adenosine are released from cardiomyocytes through which they
modulate vascular tone (19). Nevertheless, it is also well recognized that hemodynamic changesinduced release of mediators are also involved in RH; a sudden increase in flow after reperfusion
activates shear stress-sensitive mechanisms (21, 41, 52, 61), illustrating the release of
endothelium-dependent derived factors that may limit myogenic constriction and, therefore,
modifying the RH time or flow repayment area. In fact, recent reports have established the
contribution of H2O2 in flow-induced dilation of isolated human coronary arteries (29) and in
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reactive dilation of rat isolated coronary arterioles (20). Therefore, in this study, as EDHF in
humans and mice (26, 27, 58), we also investigated the role of H2O2 in CF changes during
coronary RH using isolated heart (compared with isolated vessels). Additionally, due to the
involvement of both adenosine and H 2O2 as metabolic factors regulating CF, in this study, we
also tested the involvement of H 2O2 in AR-induced effect in CF regulation and RH. We showed
for the first time that in the presence of catalase, which breaks down H 2O2 into water and oxygen,
adenosine-induced increase in CF is abolished in WT, A2AKO (where A2BAR is the only AR
mediating vasodilation), and A2BKO (where A2AAR is the only AR mediating vasodilation)
(Figure 5), showing that H2O2 plays a role in A2AR-mediated signaling pathway when inducing
an increase in CF. In this study, we also showed for the first time that the RH repayment time and
volume (flow repayment area) in addition to flow debt-to-repayment ratio were significantly
decreased in WT isolated mice hearts in the presence of catalase, showing the contribution and
release of H2O2 during coronary RH. Furthermore, since catalase decreased the flow debt-torepayment ratio in both A2AKO and WT mice with no difference compared to each other and
compared to A2AKO in the absence of catalase, we suggest that H2O2 released during coronary
RH is, at least partly, mediated through activation of A 2AARs. Showing that catalase significantly
decreased peak flow in WT and A2AKO mice (while peak flow of A2AKO was not different
compared with WT mice in the absence of catalase), may further signify that H2O2 may also be
released through activation of other pathways. Nevertheless, using patch clamp studies, we
showed that H2O2 increases glibenclamide (KATP channels blocker) sensitive currents. Putting
together these findings with our previous and current results, showing that adenosine activates
KATP channels by means of its A2ARs, we are suggesting that, at least partly, H2O2 couples the
activation of ARs to K ATP channels during coronary RH. Nevertheless, further in vivo and in vitro
studies are needed to fully elucidate the complex mechanisms of action involved in RH. We also
have to highlight that the magnitude of hyperemia is also determined by the baseline flow. In this
study, we observed that H2O2 or knocking out of the A2AARs, solely, do not decrease the baseline
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CF; however, synergistically they significantly decrease the CF baseline, which by itself may
suggest that there might be a compensatory relationship between A2AARs and H2O2 (Table 1).
Since, in this study, we used isolated heart, the contribution of flow/shear stress- or
pressure-dependent coronary mechanisms in the development of RH could not be clearly
elucidated or isolated from the effect of local metabolic factors. However, an ex vivo isolated
heart model certainly provides us with more valuable data closer to the physiological in vivo
responses compared with in vitro isolated vessels, since it reflects the overall end effect of
shear/pressure stress- and metabolites-induced effects during coronary RH. Additionally, an ex
vivo study, such as the current study, eliminates the complexity of the role of neuronal and
hormonal effects and, hence, enabling us to better understand the tissue selective responses and
mechanisms involved during coronary RH. We also have to mention a second limitation of our
study that has to do with performing patch clamp experiments on smooth muscle cells from aorta,
as a model to complement functional studies from the coronary arteries. Perhaps a better
approach would be to study smooth muscle cells isolated from mouse coronary arteries or
arterioles. However, to our knowledge, there are no reports using mouse coronary smooth muscle
in patch clamp setting in order to study ion channel currents due to its own limitations such as
isolation and experimental procedures required. Therefore, most studies investigating coronary
ion channels show currents from aorta as a tool (5, 23, 28). Also, KATP channels are known to be
important regulators of coronary vascular tone in mice (5, 28). Thus, aortic smooth muscle cells
appear to be an appropriate substitute for coronary smooth muscle cells in this regard.
The release of H2O2, as endothelium-derived hyperpolarizing factor (EDHF) in mice and
humans (26, 27), could be induced by various factors. Morikawa et al. suggested that Cu,Zn-SOD
plays an important role as an EDHF synthase in mice (31). It is also likely that H2O2 is produced
from superoxide anions from several sources in endothelium, such as eNOS, lipoxygenase,
cytochrome p-450 enzymes, and NADPH oxidases (27). Further, it is reported that adenosinemediated effects are partially endothelium dependent and that adenosine also induces vasodilation
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through production of cytochrome p-450 metabolites (34, 35), NO (50), and NADPH oxidases
(data not shown). Therefore, comparing these signaling pathways, one may speculate that
adenosine-induced release of H2O2 may involve activation of epoxygenases pathway, eNOS, or
NADPH oxidase. However, further studies are needed to identify these signaling pathways.
It is known that H2O2 induces vasodilation; however, there are also reports showing that
H2O2 induces vasoconstriction (8, 16, 30) and that H2O2 inhibits vasodilation to adenosine in
isolated porcine coronary arteries (51). Nonetheless, it was suggested that the vascular effect of
H2O2 depends on its concentration (8). To the best of our knowledge there is limited information
on the endogenous level of H 2O2, however, H2O2 levels between 2.5-50 µmol/L have been
reported in human plasma (9, 22, 54). Exogenous infusion of H2O2, up to 6x10-6mol/L (6µmol/L),
caused a significant increase in CF in isolated mouse heart (data not shown) from which point
onward (at 10-5mol/L ) H2O2 started to induce coronary vasoconstriction which was also
accompanied by a decrease in left ventricle pressure and +dp/dt (data not shown). It seems that
endothelial cells are less vulnerable to H 2O2 since a relatively high concentration of H2O2 >200
µmol/L is generally required to produce irreversible endothelial barrier dysfunction (40, 56).
Therefore, H2O2-induced decrease in CF at 10-5mol/L concentration may be due to H 2O2-induced
damaging effect on cardiomyocytes. Nevertheless, our study showed a significant increase in CF
between 10-6- 6x10-6mol/L. Therefore, the discrepancy between our study and other studies
regarding H2O2-induced effects may be dependent on the level of H 2O2 released. For example,
Thengchaisri et al. showed that H2O2 in concentrations below 10 µmol/L did not modify NOmediated vasodilatory responses. Such variations may also be dependent on the species, vascular
beds, and experimental models such as ex vivo vs. in vitro. However, overall, we can only
speculate that H2O2 concentration released due to coronary RH may be in the range of 10 -6- 6x106

mol/L.
It is well established that activation of K ATP channels plays a major role in coronary RH

in addition to its contribution to AR-mediated CF changes (2, 48, 62). However, identification of
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the factor(s) that activates these channels was not assessed in previous studies. Recent studies
have shown the association of K + ions in H2O2–induced vasodilation (42, 43, 45). These channels
were also shown to mediate, at least in part, H2O2-induced dilation of arterioles from skeletal
muscle and brain (25, 55). Further, it has been shown that H2O2 activates KATP channels in
pancreatic beta cells and cardiac myocytes (18, 33). Nevertheless, direct evidence of this
mechanism in smooth muscle and the role of adenosine as the inducer of this mechanism is
lacking. In this study, we showed for the first time that KATP channels on smooth muscle cells are
activated by H2O2 and, at least partly, adenosine induces the release of H 2O2 and, hence,
activation of KATP channels. It is worth mentioning that A2AR-induced increase in CF is through
activation of non-mitochondrial KATP channels (48) and, therefore, one can speculate that at least
the source of H2O2-induced CF changes in RH due to activation of ARs may not be mitochondria
related. However, further experiments are needed to better understand the role of mitochondrial
and non-mitochondrial KATP channels in RH coronary flow responses.
Finally catalase induced a decrease in adenosine-induced increase in LVDP. This
inhibition may be due to Gregg’s effect since at this concentration adenosine has significantly
increased both CF and LVDP. The opening of KATP channels may also affect the contractility
independent of CF changes. It is worth mentioning that adenosine is shown to activate K ATP
channels and that glibenclamide, a KATP channel blocker, is reported to decrease reactive oxygen
species (36). Nevertheless, further studies are needed to better understand the role of H 2O2 in
LVDP.
This study is another step in the direction of better understanding of the CF regulation
and its heterogeneity that may help us towards development of treatments for various clinical uses
such as evaluation of endothelial integrity and reperfusion of coronary arteries after an embolism.
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CONCLUSION
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The work presented in this dissertation confirms the heterogeneity of coronary
flow responses mediated by activation of adenosine receptors (AR). In this dissertation,
we established that A2A/B AR subtypes may have differing contributions in the regulation
of CF under varying conditions.
We suggested that out of all four AR subtypes, A2AARs and A2BARs induce
coronary artery (CA) vasodilation, since exogenous adenosine did not induce any
increase in CF in A2A/2BAR double knockout mice. Additionally, each of these two AR
subtypes further compensate for the deletion of the other subtype; indeed A2AARs
expression was up-regulated in A2BKO mice. We established the presence of such
compensatory mechanism via the use of selective and non-selective agonists and
antagonists. Furthermore, since some inconsistencies are reported between the results
obtained from pharmacological and molecular (knockout mice) approaches, we also used
AR knockout mice to further confirm our findings. The differing expression of A2A/2B
ARs is reported in many cardiovascular diseases and, therefore, the knowledge of the
presence of such compensatory mechanisms between A2A and A2B ARs may contribute to
the future development of new treatment approaches. In fact, A2ARs are being
investigated as a treatment during percutaneous coronary intervention for the reduction of
myocardial reperfusion injury in patients with myocardial infarction, which is well
established to be associated with worsening of cardiac injury and function.
The next step was to determine the effector, located on SMCs, causing the final
effect of coronary vasodilation mediated by activation of A2ARs. We not only learned
that both A2AAR- and A2BAR-mediated CF effects are via activation of nonmitochondrial KATP channels but, we suggest that, no matter what the A2 AR-induced
coronary vasodilation signaling pathway may be, it may be through activation of K ATP
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channels since both A2AAR- and A2BAR-meditaed CF effects were abolished in the
presence of glibenclamide (Figure 3.7).
Whereas we showed that activation of both A2AARs and A2BARs induces CF
vasodilation, in this dissertation we established that only A2AARs contribute to the
regulation of CF in reactive hyperemia, where the metabolic factors are known to be
mainly involved. It is interesting to mention that A2AARs induce the sustained coronary
vasodilation during reactive hyperemia through the release of H2O2. H2O2, depending on
the vascular bed and its concentration, acts as a vasorelaxing as well as a vasoconstricting
factor. Using isolated mouse hearts, we showed that exogenous H2O2 may have a tissueprotective role by inducing coronary vasodilation. In addition, we established that H2O2,
released due to activation of A2AARs, also activates KATP channels on smooth muscle
cells, which further confirms our findings that KATP channels may be the end effector in
A2 AR-mediated effect on CF (Figure 5.1).
The availability of single and double knockout ARs is a valuable tool to better
understand the role of each AR or a subclass of AR subtype. In addition to measurement
of baseline parameters, such as baseline CF, heart rate, and left ventricle developed
pressure, we also showed that the recently available A2BKO mice have a functional
endothelium by showing that bradykinin response was not different in A2BKO mice
compared with wild type mice.
In summary, both A2A and A2B ARs are capable of inducing coronary
vasodilation, but they each are activated endogenously under different conditions.
Needless to say, the role of A2ARs in the regulation of CF is much more complicated
than what has been described in this thesis. It is possible that there might also be other
interactions present between this class of GPCRs and β adrenoceptors, in view of the fact
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that NECA-mediated increase in CF is ameliorated in β1/β2 double knockout mice
(Appendix A). These findings require more detailed investigation to better understand the
interaction between ARs and β adrenoceptors.
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Figure 5.1 Suggested signaling pathways for A2A- and A2B ARs-mediated CF
regulation
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Future Directions
The next step for this project would be to identify the source of H2O2; H2O2 may
be released from the myocardium or the vascular bed itself, in which case, the knowledge
of whether the source is the endothelium or SMCs may help us to identify the mechanism
behind reduced adenosine coronary response in patients with cardiovascular disease.
Furthermore, it would be interesting to identify the factor(s) responsible for the release of
superoxide, which subsequently leads to the formation of H2O2 ; among the possible
factors, NADPH oxidases and mitochondria are the primary candidate sources of
superoxides (Figure 5.2).
The NADPH oxidase-enzyme complex consists of two membrane-bound
components (gp91phox [also known as NADPH oxidase (Nox)-2] and p22phox) and
several cytosolic regulatory subunits, including p47phox, p67phox, and the small GTPase
Rac (Rac1 or Rac2). When NADPH oxidase becomes activated, the cytoplasmic subunits
translocate to the cell membrane and the resulting complex transfers electrons from
NADPH to molecular oxygen in order to form superoxide. In fact, NADPH oxidase is
identified as a major source of superoxide in ECs, and, therefore, the important
determinants of the oxidation-reduction (redox) state of the endothelium. Investigators
have also identified NADPH oxidase complex as the major source of ROS in VSMCs.
Whereas both p22phox and p47phox appear to be essential for NADPH oxidase activity
in VSMCs, targeted-deletion of the gp91phox gene in mice had no effect on superoxide
production (3). Additionally, two homologues of gp91phox, termed Nox1 and Nox4, are
suggested to be mainly present on vascular beds. Therefore, the association of the
NADPH oxidase homologue involved in adenosine-mediated release of H2O2, and hence
coronary vasodilation, needs to be clarified.
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In many cells, the majority of superoxide is generated from mitochondria via
cellular respiration and specifically during ubisemiquinone autoxidation. Ubisemiquinone
can serve as an electron donor to O2 to produce superoxide. Electron flow through the
mitochondrial electron transfer chain occurs by four inner membrane–associated enzyme
complexes, with cytochrome c and the mobile carrier ubiquinone. NADH derived from
both cytosol and mitochondria donate electrons to NADH:ubiquinone oxidoreductase
(complex I) which then transfers its electrons to succinate:ubiquinone oxidoreductase
(complex

II).

Electrons

from

reduced

ubiquinone

are

then

transferred

to

ubiquinol:cytochrome c oxidoreductase (complex III). Electron transport then proceeds
through cytochrome c, cytochrome c oxidase (complex IV), and finally, molecular
oxygen (5-6). Nevertheless, there are two major mitochondrial electron transfer chain
regions where ROS are produced: complex I and complex III. Therefore, in order to
identify the mitochondrial complex involved in H 2O2 production, we can use rotenone, a
complex I inhibitor, myxothiazol, which inhibits oxidation of ubiquinol to
ubisemiquinone in complex III, and cyanide, a complex IV inhibitor, to detect if the
trapped radical species originates from the electron transport chain of the mitochondria.
Cardioprotective effect of carvedilol (βADR blocker) was shown to be through an
adenosine-dependent mechanism. Additionally, it was reported that βADR-mediated
inotropic responses were attenuated by adenosine (7). Our preliminary data also
establishes a relationship between βADRs and A2ARs since the effect of NECA is
attenuated in β1/β2DKO mice. Therefore, a better understanding of the relationship
between ARs and βADRs in CF regulation and the possible signaling pathways involved,
would open a new window to better understand the heterogeneity CF regulation in
relation to ARs. Our preliminary data show that, like any complex system, regulation of
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CF may further involve an interaction between ARs and βADRs. Nevertheless, this
investigation requires further experiments to confirm the presence of such a relationship
between these two classes of GPCRs.
Finally, our data show that A2BARs are not involved in RH and may play a role in
severe ischemic conditions, where adenosine levels are significantly higher. Therefore, in
order to better clarify the role of A2BARs in CF regulation, further experiments such as
ischemia/reperfusion experiments are needed. Indeed, is has been reported that A2BARs
play a cardioprotective role during ischemia/reperfusion (1-2, 4). Therefore, taken
together, elucidation of CF regulation and cardioprotection in light of A2BARs and
βADRs, and, ultimately, understanding the signaling pathways involved, would lead to
uncovering of the translational mechanisms of cardiac reperfusion subsequent to a heart
attack, in addition to finding of better and complete ways of cardiac imaging evaluation
for the diagnosis of coronary artery disease (Figure 5.2).
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Figure 5.2 Future directions for identifications of A2AARs and A2BARs signaling
pathways in the regulation of CF
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APPENDIX A
Preliminary experiments (relationship between adenosine receptors and β 1 and β2
adrenoceptors) were carried out. The concentration-response curve for NECA was
calculated in WT (FVB) and β2KO mice isolated hearts. This was done to determine
the role of A2ARs in NECA-induced relaxation in β2KO. There was no difference
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Preliminary experiments (relationship between adenosine receptors and β 1 and β2
adrenoceptors) were carried out. The concentration-response curve for NECA was
calculated in WT (FVB), WT (C57), and β1/2DKO mice isolated hearts. This was
done to determine the role of A2ARs in NECA-induced relaxation in β1/2DKO. There
was no difference between the two control groups while NECA-mediated effects

Coronary flow
(%change of baseline)

were significantly diminished in β1/2DKO compared to both controls.
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Preliminary experiments (relationship between adenosine receptors and β 1 and β2
adrenoceptors) were carried out. The concentration-response curve for CCPA was
calculated in WT (FVB) and β1/2DKO mice isolated hearts. This was done to
determine the role of A1AR-mediated effect in β1/2DKO. There was no difference
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